Healthcare & Life Sciences — April 17, 2026

NCT07536243: Emotion Regulation RCT for Eco Anxiety and Eating Concerns in Mexican Adults

The National Institutes of Health registered clinical trial NCT07536243, a randomized controlled trial evaluating a group-based emotion regulation intervention for eco-anxiety and eating-related eco-concerns in Mexican adults aged 18 and older. The six-week intervention will be assessed at baseline, post-intervention, and four-month follow-up, comparing the treatment group to a control group. Participants will attend weekly sessions and complete assessment instruments at three time points.

Comparative Efficacy of Electromagnetic Field Therapy and Tibial Nerve Stimulation in Urge Urinary Incontinence

NIH registered Clinical Trial NCT07536139 on ClinicalTrials.gov, a prospective, randomized, assessor-blinded clinical trial comparing pulsed electromagnetic field (PEMF) therapy and posterior tibial nerve stimulation (PTNS) for treatment of urge urinary incontinence in women. Eligible participants will be randomized to one of two intervention groups and assessed at baseline and post-treatment using validated instruments including the ICIQ-SF, bladder diaries, and quality-of-life scales. The primary objective is to compare efficacy of the two modalities in reducing urinary symptoms. No compliance obligations or deadlines are imposed by this registration record.

CIRCLE-Asia Phase 3 Trial: Colchicine for Chronic Limb-Threatening Ischemia

The CIRCLE-Asia trial (NCT07536373) is a Phase 3 randomized, double-blind, placebo-controlled multicenter study evaluating colchicine 0.5mg daily versus placebo in 200 adult patients with chronic limb-threatening ischemia who have undergone successful revascularization. The trial will be conducted at five hospitals in Taiwan with treatment beginning within 7 days of the procedure. Participants will be monitored for reduction of complications and limb events.

OCU500 ChAd36 Vector COVID-19 Vaccine Phase 1 Trial, 80 Participants

A Phase 1 randomized, open-label, dose-escalation clinical trial registered for OCU500, a ChAd36 vector vaccine encoding SARS-CoV-2 spike protein, administered via intranasal and inhalational routes. The trial enrolls 80 healthy adults (aged 18-64) previously vaccinated with a primary COVID-19 series and at least one booster. Participants will receive one of two dose levels (1×10^10 VP or 5×10^10 VP) across four study arms of 20 participants each, with the primary objective of evaluating safety and reactogenicity.

Methadone Perception Survey Targets Pediatric Surgical Caregivers

An observational survey study (NCT07537608) examining methadone perceptions among caregivers of pediatric outpatient surgical patients, orthopedic surgeons, and anesthesiologists has been registered on ClinicalTrials.gov. The study will investigate associations between social determinants of health and attitudes toward methadone use for postoperative pain. Healthcare providers and clinical researchers should monitor this registry for emerging evidence on potential disparities in pain management perceptions.

AI LSTM Forecasting Depth of Anesthesia Trial

The National Institutes of Health registered observational clinical trial NCT07536230 on ClinicalTrials.gov, investigating the use of Long Short-Term Memory (LSTM) deep learning networks to forecast depth of anesthesia. The study aims to deploy AI frameworks to predict patient-specific physiological states by processing time-series BIS-EEG data, moving beyond traditional PK/PD models like the Eleveld model for Propofol and Remifentanil. This trial involves adult patients undergoing procedures requiring general anesthesia and will evaluate the predictive accuracy of AI-driven forecasting versus standard concentration estimation models.

Observational Study of Pre-Anaesthesia Person-Centred Care in Danish Hospitals

The NIH ClinicalTrials.gov registry has published registration details for observational study NCT07535450, an observational study examining pre-anaesthesia practices and patient experiences in Danish public hospitals. The study will collect patient survey data on what matters to patients before anaesthesia and the degree of person-centredness in pre-anaesthesia consultations.

i-PRF Perfusion Trial for Moderate to Severe Intrauterine Adhesions

NIH's ClinicalTrials.gov registered a new prospective randomized controlled study (NCT07536971) evaluating the efficacy and safety of intrauterine i-PRF (injectable platelet-rich fibrin) perfusion in women with moderate to severe intrauterine adhesions after hysteroscopic adhesiolysis. The trial will compare i-PRF intrauterine perfusion against sodium hyaluronate intrauterine treatment, assessing endometrial regeneration and reproductive outcomes. The anticipated study start date is April 17, 2026.

SPSIP Block vs Rhomboid Block for Postoperative Analgesia in Breast Cancer Surgery: Randomized Controlled Trial

This ClinicalTrials.gov registry entry announces a randomized controlled trial (NCT07536867) comparing the analgesic efficacy of Serratus Posterior Superior Intercostal Plane (SPSIP) Block versus Rhomboid Intercostal Block for postoperative pain management following breast cancer surgery with axillary lymph node dissection. The primary outcome is Visual Analog Scale pain scores during the first 24 hours post-surgery. Secondary outcomes include opioid consumption, rescue analgesia requirements, block performance time, and patient satisfaction. The study is currently recruiting.

Phase 2 Auricular Point Stimulation Plus Dexamethasone for Chemotherapy-Induced Nausea and Vomiting (NCT07537699)

NIH ClinicalTrials.gov registered a Phase 2 clinical trial (NCT07537699) evaluating auricular point stimulation combined with dexamethasone for preventing chemotherapy-induced nausea and vomiting in breast cancer patients receiving docetaxel plus cyclophosphamide. The single-arm study will track nausea, vomiting, appetite, and gastrointestinal function from Day 1 through Day 5 of chemotherapy. Participating institutions and investigators must conduct the trial in accordance with the registered protocol, IRB oversight, and informed consent requirements.

Telerehabilitation in Patients With Elevated Pulmonary Artery Pressure

NIH registered clinical trial NCT07535398 on ClinicalTrials.gov studying whether synchronous telerehabilitation improves exercise capacity, dyspnea, fatigue, functional status, and quality of life in patients with elevated pulmonary artery pressure (systolic PAP ≥50 mmHg). The randomized controlled trial will compare an 8-week telerehabilitation program (3 sessions/week, 30 min/session) against breathing and posture exercises. Estimated completion date is April 17, 2026.

PIKFYVE Inhibitor Compounds Patent Application - C07D 487/04

European Patent Office published patent application EP4444316A1 for PIKFYVE inhibitor compounds and pharmaceutical compositions. The application, filed by Kineta, Inc., covers heterocyclic compounds (C07D 487/04) with therapeutic applications including neurological conditions (A61P 25/28). Inventors include Kumaravel, Macdonnell, and Peng. A1 publication indicates the application has entered the European phase and is publicly available for examination.

Organic Molecules for Optoelectronic Devices - Samsung Display EP4472973A1

The European Patent Office granted Samsung Display Co., Ltd. Patent EP4472973A1 for organic molecules used in optoelectronic devices. The patent covers compounds classified under C07D 405/14 and H10K with applications in display technology. The designation covers 31 European contracting states including major markets such as DE, FR, GB, IT, and ES.

EP4426712A1 - Processable Compositions Patent

The European Patent Office published patent application EP4426712A1 filed by Ripple Therapeutics Corporation on April 8, 2026. The patent covers processable compositions including steroidal compounds and heterocyclic derivatives with potential therapeutic applications spanning cardiovascular treatments, glaucoma, and ocular hypertension. The designated contracting states cover all major European Economic Area nations including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

PSMA Targeting Ligand Compound for Prostate Cancer Diagnosis and Treatment

The European Patent Office published patent application EP4431503A1 filed by Chengdu StarRay Therapeutics Co., Ltd. covering ligand compounds that target PSMA (Prostate-Specific Membrane Antigen) for use in prostate cancer diagnosis and treatment. The application includes claims for chelate compounds and their therapeutic and diagnostic applications. The patent is classified under IPC codes C07D 401/12, C07F 5/00, A61K 51/04, and A61P 35/00, covering 37 designated contracting states.

Novel PARP7 Inhibitor and Use Thereof

The European Patent Office published patent application EP4378938A1 filed by Shanghai Qilu Pharmaceutical Research and Development Centre Ltd., covering a novel PARP7 inhibitor and its therapeutic use. The application was published on April 8, 2026 under IPC classification C07D 403/10 (A61P 35/00 for anticancer indications). The designated states cover all major European Patent Convention contracting states including DE, FR, GB, IT, ES, NL, BE, CH, and others.

Hinova's Heterocyclic AR Degrader EP4378936A1

The European Patent Office published patent application EP4378936A1, filed by Hinova Pharmaceuticals Inc., covering bifunctional chimeric heterocyclic compounds designed to degrade androgen receptors for therapeutic use. The patent designates 31 EPO member states and classifies under C07D (heterocyclic compounds), A61K (pharmaceutical preparations), and A61P 35/00 (anticancer agents). The filing names 17 inventors and represents a pharmaceutical manufacturer's IP protection strategy for a targeted cancer therapy compound.

Pyrimidine Tricyclic Derivative and Pharmaceutical Application (EP4417613A1)

EPO granted patent EP4417613A1 to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. The patent covers pyrimidine tricyclic derivatives and their pharmaceutical applications. The patent is designated in multiple contracting states including DE, FR, GB, IT, ES, NL, SE, PL, and other EU member states.

Phenoxy and Benzyloxy Substituted Psychoplastogens and Uses Thereof

The European Patent Office published patent application EP4448531A1 for Delix Therapeutics covering phenoxy and benzyloxy substituted psychoplastogens and their therapeutic uses. The patent application lists designations across 31 European states and territories. The compounds are classified under IPC C07D 487/04 with therapeutic applications including neurological and psychiatric conditions such as anxiety, Alzheimer's disease, and addiction disorders.

Fused Benzoisoxazolyl Compounds as KAT6A Inhibitors

The European Patent Office published patent application EP4448109A1 for fused benzoisoxazolyl compounds as KAT6A inhibitors, filed jointly by Aurigene Oncology Limited and Olema Pharmaceuticals, Inc. The invention covers heterocyclic antineoplastic compounds classified under A61P 35/00 and C07D 498/04. The patent is designated for all European Patent Convention contracting states.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF

The European Patent Office published patent application EP2023216237A1 for JS Innomed Holdings Ltd., covering heterocyclic compounds as kinase inhibitors, compositions, and methods of use. The A1 publication indicates the application has passed formal examination and is now open for opposition. The patent covers compounds classified under IPC C07D 471/04 with therapeutic applications in A61K 31/437 and A61P 35/00 (oncology). The designated states include all current EU member states plus associated countries.

IL10 Receptor Binding Molecules and Methods of Use - EP4192880A2

The European Patent Office published application EP4192880A2, a patent for IL10 receptor binding molecules and methods of use, filed by Synthekine, Inc. The patent covers C07K peptide-based compounds under classifications C07K 16/28, C07K 14/715, and C07K 14/705. The application designates all EU member states and participating EPC contracting states including CH, LI, NO, TR, and MC.

Long Acting GLP-1 Receptor Agonists and Methods of Use

The European Patent Office published patent application EP4263587A1 for long-acting GLP-1 receptor agonists filed by I2O Therapeutics, Inc. The patent covers glucagon-like polypeptide-1 receptor agonist compositions and methods of use for treating metabolic disorders including obesity, hyperlipidemia, and diabetes. The patent is directed to peptide compounds classified under C07K 14/605 with designated protection across 31 European member states.

Modified B Cells and Methods of Use Thereof - EP4203978A1

The European Patent Office published patent application EP4203978A1 for Modified B Cells and Methods of Use Thereof, filed by Walking Fish Therapeutics, Inc. The patent covers engineered B cells for therapeutic applications, including cancer treatment indications (A61P 35/00). The application contains 18 IPC classifications spanning peptides, immunology, gene therapy vectors, and therapeutic preparations.

Tetravalent Bispecific Antibody, Preparation Method Therefor, and Use Thereof

The European Patent Office published patent application EP3967711A1 for a tetravalent bispecific antibody filed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. The application covers the antibody's preparation method and therapeutic uses. The A1 publication includes a European search report and designates 32 member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

ENPP1 Antibody Inhibitors - University of California

The European Patent Office published application EP4146706A1 for ENPP1 antibody inhibitors filed by The Regents of the University of California. The application claims anti-ENPP1 antibodies for therapeutic use, classified under IPC C07K 16/40, A61P 9/10, A61K 39/395, and C12N 15/63. The application designates all relevant European member states including AT, BE, DE, FR, GB, IT, NL, ES, PL, and 25 others.

Orthogonal Mutations for Heterodimerization - Invenra Inc.

EPO published patent application EP4259194A1 titled 'Orthogonal Mutations for Heterodimerization' filed by Invenra Inc. The invention relates to methods for creating orthogonal mutation pairs to facilitate controlled heterodimerization of proteins, with applications in bispecific antibody development and therapeutic protein engineering. The application covers 47 designated EU member and extension states including Germany, France, UK, Italy, Spain, and other EPC contracting states.

Fate Therapeutics iPSC Effector Cells for Immunotherapy Patent EP4168538A1

The European Patent Office published patent application EP4168538A1 for Fate Therapeutics, Inc., covering methods of combining iPSC-derived effector cell types for immunotherapy use. The patent includes claims related to cell therapy compositions, cytokine combinations, and therapeutic applications for cancer treatment. The patent designation covers 31 European member states.

EP4146277A1 - Avian Antibodies Reduce Viral Disease Transmission

The European Patent Office granted Patent EP4146277A1 to Camas Incorporated on April 8, 2026, covering compositions and methods for using avian antibodies to reduce viral disease transmission. The patent names nine inventors and is classified under IPC categories A61K 39/42, A61P 11/00, A61P 31/12, and C07K 16/08. The patent is designated across 31 European states including Germany, France, the United Kingdom, Italy, and Spain.

EP4200339A2 - Compositions and Methods Related to Receptor Pairings

European Patent Office granted Patent EP4200339A2 to Synthekine, Inc. covering compositions and methods related to receptor pairings. The patent application, filed with IPC classifications C07K 16/28, C07K 14/715, and C07K 14/705, lists inventors KASTELEIN Robert, LUPARDUS Patrick J., and ROKKAM Deepti. The patent is designated across all European member states.

Measles Cases Rise to 602 in Utah

The Utah Department of Health and Human Services (DHHS) has reported 602 confirmed measles cases in Utah as of April 14, 2026, since the outbreak began in June 2025. The update reminds Utahns that the MMR vaccine is 97% effective after two doses and advises those exposed to monitor their health for 21 days. Healthcare providers are urged to prepare before symptomatic patients arrive to prevent further transmission.

Effect of Tai Chi and Multimodal Exercise in Overweight and Obese Women

NIH registered clinical trial NCT07536893 examines the effects of a 10-week Tai Chi and Multimodal exercise program on balance in overweight and obese women. The study found that both Tai Chi and multimodal exercise programs significantly improved balance parameters compared to baseline. The research addresses a gap in the literature regarding balance-focused interventions as a primary goal for improving physical mobility in overweight individuals.

Evaluation of Serum Autophagic Biomarkers in Acute Response to Walking and Cycling in Healthy Males

NIH ClinicalTrials.gov registered observational study NCT07536659 evaluating serum autophagic biomarkers in healthy male individuals responding to walking and cycling exercises. The study aims to assess acute cellular responses to different physical exercise modalities through peripheral blood analysis, building on limited existing human data in this area.

First-in-man Trial TRICENTO G2 Transcatheter Valve for Tricuspid Regurgitation

The NIH ClinicalTrials.gov registry has posted a first-in-man trial for the TRICENTO G2 Transcatheter Valve System (TRICENTO G2 TVSTR) intended to treat severe tricuspid regurgitation in adult patients. The early feasibility study will assess safety, performance, and clinical benefit through 1-year follow-up. Participants will undergo minimally invasive valve implantation with clinic visits at baseline, 30 days, 3 months, 6 months, and 1 year post-procedure.

Montelukast Phase 2 Trial for Acute Myocardial Infarction

NIH registered a Phase 2 randomized controlled trial (NCT07537868) evaluating Montelukast 10 mg oral tablets for acute myocardial infarction. The trial, sponsored by Mansoura University (Egypt), will enroll participants randomized to Montelukast or placebo to assess anti-inflammatory and cardioprotective effects via inflammatory markers and cardiac injury indicators. The study has an estimated start date of April 17, 2026.

IBM Dietary Surveillance Study at Manchester Metropolitan University

The NIH ClinicalTrials.gov registry has added a new observational study (NCT07535996) titled 'IBM Dietary Surveillance Study' at Manchester Metropolitan University. The study will investigate how diet affects muscle health and functional ability in adults with inclusion body myositis (IBM) compared to healthy volunteers aged 40 and older. Participants will complete dietary records, physical activity monitoring, body composition assessments, and muscle function tests over a four-week home monitoring period plus two university visits.

Integrating Supports to Promote PrEP for Black Adolescents Working With Apps - Atlanta

NIH has registered a clinical trial (NCT07535346) evaluating the Health MPowerment app as a behavioral intervention to promote PrEP adherence among Black adolescents and young adults in Atlanta. The study applies Social Cognitive Theory to assess feasibility and acceptability of the enhanced HMP app as a support tool. The trial targets Black AYAs and adult supports as participants, with data collection anticipated through April 2026.

IPG11406 Phase 2 UC Trial, 144 Patients, 12 Weeks

NIH has registered a Phase 2 clinical trial (NCT07535489) for IPG11406, an investigational oral drug targeting the GPR183 receptor for ulcerative colitis. The randomized, double-blind, placebo-controlled study will enroll 144 adult patients across three active dose groups (10 mg, 20 mg, 40 mg twice daily) and one placebo arm over 12 weeks. The primary endpoint is clinical remission measured by modified Mayo Score at week 12, with secondary endpoints including clinical response, endoscopic remission, histological improvement, and safety evaluation.

First-in-human SRP-1005 Huntington's Disease Phase 1 Trial

NIH ClinicalTrials.gov registered a first-in-human Phase 1 trial (NCT07536061) studying SRP-1005, an investigational treatment for Huntington's Disease. The multi-center trial will evaluate the safety and tolerability of SRP-1005 versus placebo in participants with Huntington's Disease. The trial has an anticipated start date of April 17, 2026.

ctDNA-driven Anti-EGFR Retreatment Metastatic Colorectal Cancer Study

NIH's ClinicalTrials.gov registered NCT07536113, an observational, retrospective, international multicenter study evaluating anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC patients. The study, funded by Fondazione Oncologia Niguarda ETS, will screen patients for RAS/BRAF/PIK3CA ctDNA status via liquid biopsy within the MEN1611-02 C-PRECISE-01 trial and collect molecular, clinical, and outcome data already available at participating centers.

Time to Healing in Displaced Pediatric Diaphyseal Forearm Fractures Treated With Bioabsorbable Compared to Titanium Intramedullary Nails

NIH has registered a new clinical trial (NCT07536581) comparing bioabsorbable intramedullary nails to titanium elastic intramedullary nails for treating displaced pediatric diaphyseal forearm fractures. The randomized controlled trial will assess fracture healing time on X-ray, complications, recovery, function, and family experience. Children requiring surgery will be randomly assigned to either treatment group.

Mirror Therapy for Complex Regional Pain Syndrome in Post-Stroke Patients

The NIH ClinicalTrials.gov registry has registered a clinical trial (NCT07537465) evaluating mirror therapy for complex regional pain syndrome in post-stroke patients. The randomized controlled trial will compare mirror therapy to sham mirror therapy over 4 weeks. Participants will receive conventional rehabilitation therapy and be assessed using clinical scales, electrophysiological tests, and ultrasonographic measurements.

Phase 2 FAPI-74 PET/CT Inflammatory Disorders Study

NIH registered Phase 2 clinical trial NCT07535554 to evaluate [18F]-AlF-FAPI-74 PET/CT diagnostic performance in three inflammatory disorder cohorts: fever of unknown origin, IgG4-related disease, and axial spondyloarthritis. The study will compare the new radiopharmaceutical against standard-of-care [18F]-FDG PET/CT imaging.

Insulin Insitu-Gel for Tympanic Membrane Perforations: Early Phase 1 RCT

NIH ClinicalTrials.gov registered Early Phase 1 trial NCT07535827 evaluating insulin insitu-gel formulation for tympanic membrane perforation healing. The randomized controlled study at Minia University Hospital enrolled participants from January 2025 to March 2026, comparing insulin insitu-gel (Humulin with chitosan, polyvinyl alcohol, and Pluronic F127) against foam control. Primary outcome was perforation healing at 1-week, 1-month, and 2-month follow-ups; secondary outcomes included hearing scores. Results showed significantly superior healing in the insulin group versus control.

Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease

NIH has registered a clinical trial (NCT07536542) on ClinicalTrials.gov to study the effects of dual-task training on upper extremity function and muscle thickness in individuals with Parkinson's disease. The randomized controlled trial will enroll approximately 60 participants who will be assigned to either an 8-week dual-task training group (3 days per week) or a control group receiving routine care. Researchers will assess upper extremity function, grip strength, pinch strength, and muscle thickness via ultrasonography at baseline and post-intervention.

EUS-RFA for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

NIH ClinicalTrials.gov has registered a clinical trial (NCT07536087) evaluating endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) as a treatment for pancreatic cystic neoplasms and pancreatic neuroendocrine tumors in patients ineligible for or refusing surgery. The primary endpoints assess technical feasibility and effectiveness, while secondary objectives evaluate safety and long-term efficacy including adverse events and disease progression over one year of follow-up.

Observational Study, Adolescent Rights, Rural Assiut, Egypt

NIH registered observational study NCT07536555 on ClinicalTrials.gov, titled 'Adolescent Rights Fulfilment in Rural Assiut, Egypt'. The community-based cross-sectional study will assess fulfilment of adolescent rights in health, education, protection, and community participation among 300 adolescents aged 15-19 years in Beni Adi village, Assiut Governorate. Data collection is anticipated to begin April 17, 2026.

Phase 2 Leucine-Restricted Diet, Gastric Cancer Study

NIH's ClinicalTrials.gov has registered Phase 2 trial NCT07537361 evaluating the safety and efficacy of a leucine-restricted diet combined with neoadjuvant chemotherapy and immunotherapy in gastric cancer patients. The study aims to assess whether dietary leucine restriction is safe, well-tolerated, and capable of promoting immune cell activation within the tumor microenvironment to improve patient outcomes. Estimated study completion date is April 17, 2026.

House Wellness Foods Probiotic Therapeutic Patent Granted

The USPTO granted Patent US12599638B2 to House Wellness Foods Corporation for a feed and composition comprising Lactobacillus plantarum strain L-137 and a fatty acid. The patent covers compositions for enhancing IL-12 production, immunostimulation, and bacteriostasis. The patent application was filed on September 21, 2021, with 7 claims granted.

Signum Biosciences Chia Seed Extract Patent Granted

The USPTO granted patent US12599642B2 to Signum Biosciences Inc on April 14, 2026. The patent covers compositions derived from Salvia hispanica (chia) seeds and methods of preparation and administration. The 18 claims span dermatological applications including skin care and sunscreen formulations. Third parties face no compliance obligations from this patent grant.

DOJ Sues NYPH Hospital for Antitrust Violations

The DOJ filed an antitrust lawsuit against The New York and Presbyterian Hospital on March 26, 2026, alleging the hospital used its Manhattan market power to force payors into favorable contractual terms that harmed patients and employers. The complaint closely follows a template used in a similar February 2026 lawsuit against OhioHealth, with approximately half of the 60 paragraphs being nearly identical. The NYPH lawsuit differs in that it does not include state law claims (the NY State AG did not join) but contains more documented evidence suggesting the DOJ has incriminating emails from NYPH representatives.

FDA Expands Home Devices, Seeks Statutory Authority Changes

This Mintz newsletter covers two FDA regulatory developments: (1) FDA's READI-Home innovation challenge inviting medical device manufacturers to submit home-health devices aimed at reducing hospital readmissions, with submissions due September 30, 2026 and selections by December 4, 2026; and (2) HHS's FY2027 budget request containing FDA legislative proposals including changes to compounded drug advertising rules, a new biological product licensure pathway, and an alternative IND pathway for Phase 1 clinical trials to encourage biotechnology investment.

LEAD Replaces ACO REACH, 10-Year Model Starts 2027

The Centers for Medicare & Medicaid Services Innovation Center announced the Long-term Enhanced ACO Design (LEAD) model to replace the ACO REACH model. LEAD offers a 10-year commitment (2027-2036) with a fixed spending baseline, eliminating the benchmark rebasing that reduced savings under REACH. The model opens participation to smaller, rural, and independent practices and adds new payment tools including Non-Primary Care Capitation (NPCC) for specialists and CARA risk arrangements. ACOs must apply by May 17, 2026, for the first performance year starting January 1, 2027.

Health Care Non-Compete Legislation Q1 2026 Update

Several states enacted new restrictions on non-compete agreements for healthcare workers in Q1 2026. Washington passed H.B. 1155 banning all non-compete covenants effective June 30, 2027. Virginia enacted a law prohibiting non-compete enforcement when employees are terminated without cause unless severance is provided, and passed legislation broadly prohibiting non-competes with health care professionals pending the governor's signature. Utah prohibited non-compete agreements with health care workers effective May 6, 2026. Montana expanded its physician non-compete ban effective January 1, 2026. California enacted legislation targeting private equity and hedge fund influence in healthcare practices.

Federal Circuit Reverses JMOL on Antibody Patent Claims for Method of Treatment

The Federal Circuit reversed a district court JMOL and held that Teva's method of treatment claims using anti-CGRP antagonist antibodies to treat headaches satisfied both written description and enablement requirements under 35 U.S.C. § 112. The court found that the prior art demonstrated the antibody genus was well known, humanization methods were routine, and all antagonistic anti-CGRP antibodies work for headache treatment. The decision clarifies that method-of-treatment claims with a specific indication differ from broad functional claims requiring disclosure of every species in a genus.

Storm Flood Cleanup Safety Precautions for Wisconsin Residents

The Wisconsin Department of Health Services has issued safety precautions for residents and crews engaged in storm and flood cleanup and recovery. The advisory covers multiple hazards including downed power lines, debris, carbon monoxide exposure, floodwater dangers, mold growth, private well contamination, and food safety. The guidance also informs FoodShare members they have 10 days to request replacement benefits for food lost due to storms or power outages.

Proton vs Photon IMRT Toxicity in Breast Cancer (NCT07537712)

NIH registered clinical trial NCT07537712, an observational study comparing acute and long-term toxicities between intensity-modulated proton therapy (IMPT) and intensity-modulated photon radiotherapy (IMRT/VMAT) in postoperative breast cancer patients. The study will follow eligible patients for at least one year to assess incidence and severity of toxicities affecting the heart, lungs, skin, esophagus, thyroid, and lymphatic tissues, as well as patient-reported outcomes, cosmetic outcomes, and quality of life. The trial has an estimated completion date of April 17, 2026.

Effect of Sildenafil on Left Ventricular Function in Pediatric Primary Dilated Cardiomyopathy

NIH registered observational study NCT07536880 titled 'Effect of Sildenafil on Left Ventricular Function in Pediatric With Primary Dilated Cardiomyopathy.' The study examines sildenafil's effect on left ventricular function in pediatric patients with primary dilated cardiomyopathy, characterized by left ventricular dilation and impaired contraction. The study was registered on April 17, 2026.

BCD-261 Phase 1 Study, Healthy Chinese Volunteers

NIH ClinicalTrials.gov registered a Phase 1 study for investigational drug BCD-261, a single subcutaneous injection, to evaluate safety, pharmacodynamics, pharmacokinetics, and immunogenicity in healthy adult Chinese volunteers. The study (NCT07535775) represents early-stage clinical research.

Arterial Vascular Effects of Estetrol-drospirenone Combined Oral Contraceptive Pill

The NIH registered a Phase 3 clinical trial (NCT07536763) comparing estetrol-drospirenone combined oral contraceptive pills against ethinylestradiol-levonorgestrel pills. The trial will evaluate effects on arterial vascular function including flow-mediated dilatation and pulse wave velocity, blood pressure, inflammatory markers, and metabolic indices over 12 months. Participants are randomized to receive either treatment with clinic visits at baseline, 6 months, and 12 months.

Becotatug Vedotin Phase 2 Hepatocellular Carcinoma Study

NIH registered a Phase 2 clinical trial (NCT07536789) for Becotatug vedotin (MRG003) in previously treated advanced hepatocellular carcinoma (HCC). The study will evaluate efficacy and safety of MRG003 as an intervention. No compliance obligations or deadlines are imposed by this registration.

Diagnostic Accuracy and Prognostic Value of 18F FDG PET-CT in Follow-Up of Colorectal Carcinoma

NIH ClinicalTrials.gov registered observational study NCT07536321 evaluating the diagnostic and prognostic value of 18F FDG PET-CT imaging in the follow-up of patients with Stage III rectal cancer. The 5-year prospective study will enroll participants already undergoing routine PET-CT imaging and assess whether PET-CT contributes to treatment decision-making in colorectal cancer patients.

Support Group Curriculum for Parents of Children With DLD

NIH registered clinical trial NCT07536217 titled 'Developmental Pilot of Support Groups for Caregivers of Children With DLD' to test a new support group curriculum designed for parents of children with Developmental Language Disorder. The study will evaluate support groups as the intervention approach for this population.

0.01% and 0.025% Atropine Eye Drops Combined With Auricular Acupoint Stimulation for Myopia Control in Children

NIH has registered a randomized, double-blind, placebo-controlled pilot trial (NCT07537166) evaluating low-dose atropine (0.01%, 0.025%) combined with auricular acupoint stimulation for myopia control in 420 children aged 6-12. Participants will be divided into six groups receiving different treatments or placebo over a 12-week follow-up period. The study aims to determine synergistic effects of combined therapy and establish safer treatment options for myopia, addressing corneal toxicity concerns associated with higher 0.05% atropine concentrations.

Radiofrequency Versus Cervical Fusion for Chronic Whiplash Observational Study

The NIH ClinicalTrials.gov registry has published registration details for NCT07535515, an observational study comparing cervical medial branch radiofrequency ablation versus anterior cervical discectomy and fusion (ACDF) for chronic post-traumatic whiplash patients. The retrospective study reviews medical records from a tertiary hospital spanning 2005-2025 to evaluate pain relief, functional disability, psychological symptoms, and need for repeat procedures.

Comparison of Effectiveness of Autobrush vs Manual Toothbrush, Children 9-12

The NIH National Library of Medicine registered clinical trial NCT07537803, a randomized crossover study comparing the effectiveness of an Autobrush U-shaped toothbrush versus a manual regular toothbrush in children aged 9-12 years. The study will measure Full Mouth Plaque Scores using disclosing tablets and assess both brushing techniques. Participants avoid oral cleaning procedures 12 hours before appointments.

Enzyme-Cleavable Prodrug Compositions and Controlled Release Nafamostat Methods

USPTO granted patent US12599578B2 to Ensysce Biosciences Inc. for pharmaceutical compositions including enzyme-cleavable prodrugs providing enzymatically-controlled release of active agents, combined with controlled release nafamostat. The patent covers 12 claims and methods of use for these pharmaceutical compositions.

Nanoparticle Wound Healing Treatment Patent US12599698B2

USPTO granted patent US12599698B2 to Kismet Technologies Inc. on April 14, 2026, covering a therapeutic article with metal-modified cerium oxide nanoparticles (mCNPs) for wound healing and antimicrobial infection control. The patent includes 19 claims for the nanoparticle-treated fiber composition with particles sized 3-35nm.

Lipid Triglyceride Surfactant Composition, Patent US12599580B2

The USPTO granted patent US12599580B2 to BASF AS on April 14, 2026, covering compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, a triglyceride, and a surfactant, as well as methods of using the same in self-emulsifying drug delivery systems such as SEDDS, SMEDDS, or SNEDDS. The patent contains 20 claims.

Axcess Global Sciences LLC Patent - Ketone Bodies and Amino Acid Compositions

The USPTO granted patent US12599579B2 to Axcess Global Sciences LLC covering compositions of ketone bodies or ketone body precursors complexed with amino acids. The patent, effective April 14, 2026, contains 22 claims and names Gary Millet, Ryan Lowery, Jacob Wilson, and Terry Lacore as inventors. The compositions are directed toward uses including weight loss, blood glucose management, muscle performance, metabolic repair, neurological treatment, and anti-aging applications.

NLRP3 Modulators for Treating Interleukin 1β Diseases

USPTO granted patent US12599616B2 to Zydus Lifesciences Limited for novel substituted sulfonylurea and sulfoximineurea derivatives as NLRP3 modulators for treating interleukin 1β-mediated diseases and conditions. The patent contains 11 claims and 20+ CPC classifications spanning A61K, C07C, C07D, and A61P therapeutic categories.

Grand Forks County Measles Case Confirmed, 33 Total in ND 2026

North Dakota HHS confirmed one measles case in Grand Forks County on April 16, 2026, marking the first case in that county this year. The individual likely acquired the infection within the state with no reported travel. North Dakota has recorded 33 total measles cases in 2026, with five hospitalizations. Public exposure locations in Grand Forks County have been identified. HHS recommends MMR vaccination for all Grand Forks County residents and travelers as a precaution against potential community transmission.

Neural Mobilization vs Cervical Neuromodulation in Diabetic Peripheral Neuropathy: Randomized Pilot Trial, 75 Participants

NIH registered a three-arm, assessor-blinded randomized controlled pilot feasibility trial (NCT07537270) comparing Manual Neural Mobilization and Cervical Neuromodulatory Intervention against standard care in 75 participants with diabetic peripheral neuropathy over 12 weeks. The primary endpoints are recruitment rates, adherence, and safety; secondary endpoints include HbA1c, fasting blood glucose, and pain intensity. The trial is registered in ClinicalTrials.gov as a pilot feasibility study ahead of a potential full-scale RCT.

Abdominal and Lower Extremity Adipose Tissue Elasticity in Patients With Lipedema

NIH has registered a new observational clinical trial (NCT07536646) investigating abdominal and lower extremity adipose tissue elasticity in patients with lipedema using shear wave elastography (SWE). The study will compare subcutaneous tissue stiffness between lipedema patients and healthy controls, and evaluate differences between abdominal and lower extremity measurements within the same patients. Lipedema is a chronic disorder predominantly affecting women and is often underrecognized or confused with obesity, venous insufficiency, and lymphedema.

EXTEND-TNK Registry, IV Tenecteplase, Acute Ischemic Stroke, China

The NIH ClinicalTrials.gov has registered NCT07536165, the EXTEND-TNK Registry, a prospective multicenter observational cohort study evaluating intravenous tenecteplase administered beyond 4.5 hours after last known well for acute ischemic stroke patients in routine clinical practice across China.

GALLVIA Trial: EUS-Guided vs Transpapillary Gallbladder Drainage for Acute Calculous Cholecystitis

NIH registered the GALLVIA Trial (NCT07536191), a multicenter randomized controlled trial comparing endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with endoscopic transpapillary gallbladder drainage (EGBS) in poor surgical candidates with acute calculous cholecystitis. The 1:1 randomized trial uses lumen-apposing metal stents for EUS-GBD and transpapillary plastic stents for EGBS, with primary endpoint of clinical success. Secondary endpoints include technical success, adverse events, reintervention rate, procedure time, length of stay, and 30-day mortality.

Firsekibart, Tislelizumab, Lenvatinib for TP53-Mutated HCC

NIH registered Phase 2 clinical trial NCT07535840 evaluating combination therapy with Firsekibart, Tislelizumab, and Lenvatinib in patients with unresectable, TP53-mutated hepatocellular carcinoma who have failed prior systemic immunotherapy. The study's primary objective is objective response rate, with secondary objectives assessing overall efficacy, safety, and biomarker predictors.

Comparative Efficacy of Topical Clotrimazole Versus 2% Salicylic Acid in Otomycosis

NIH has registered a randomized controlled clinical trial (NCT07535424) comparing clotrimazole ear drops versus 2% salicylic acid ear drops for treatment of otomycosis (fungal ear canal infection). The study enrolled 60 patients randomized equally between the two treatment groups, with both interventions administered three times daily for two weeks. The primary outcome measure is relief of ear blockage reflecting improvement in canal patency.

Early Delirium Prediction Via Serial EEG Trajectories and Machine Learning

NIH registered observational study NCT07536854 on ClinicalTrials.gov. The study aims to develop a machine learning model predicting delirium in trauma ICU patients using serial EEG recordings. Researchers will analyze brainwave patterns across recording conditions to identify early delirium biomarkers before clinical onset.

Fontan Outcomes in Oligemia vs Plethora in Univentricular CHD

NIH registered a prospective cohort study (NCT07535203) comparing Fontan procedure outcomes in patients with cyanotic congenital heart disease classified by pulmonary blood flow characteristics. Fifty-two patients will be divided into oligemia and plethora groups and followed for approximately 1.5 years post-procedure to assess mortality, morbidity, pulmonary hemodynamics, functional capacity, neurocognitive status, and quality of life.

Right Ventriculo-Arterial Coupling During Fluid Loading in ICU Patients

NIH registered observational study NCT07537621 examining right ventriculo-arterial coupling during fluid loading in ICU patients. The study investigates the relationship between preload responsiveness, venous congestion, and right ventricular function in critically ill patients with shock and right ventricular dysfunction. Echocardiography will be used as the primary intervention to assess hemodynamic changes.

REPRESENT-PF Registry, Observational, PFA Atrial Fibrillation

NIH ClinicalTrials.gov registered the REPRESENT-PF observational registry (NCT07535268), a pragmatic prospective single-arm multi-center study evaluating FDA-approved Boston Scientific FARAWAVE Pulsed Field Ablation catheters for treatment of atrial fibrillation in underrepresented minority patients. All data collected will be standard of care. Conditions include persistent and paroxysmal atrial fibrillation.

Cancer Exercise App Trial for Post-Treatment Survivors

NIH registered a randomized controlled clinical trial (NCT07535918) evaluating the Cancer Exercise app (CEA) designed to promote physical activity among cancer survivors who have completed treatment. The 12-week home-based exercise program will randomize 240 participants into CEA or usual care groups to measure intervention effects on physical activity levels. The trial is registered with anticipated completion in April 2026.

RecoveriX BCI System Clinical Trial for Stroke Gait Rehabilitation

NIH's ClinicalTrials.gov registered a new clinical trial (NCT07537530) evaluating the recoveriX PRO Brain-Computer Interface system for gait rehabilitation in stroke patients. The recoveriX device combines motor imagination with functional electrical stimulation and virtual reality feedback, controlled via EEG signals. The trial will enroll stroke patients and compare BCI-assisted therapy (25 sessions over approximately 8 weeks) against standard FES+VR treatment without EEG monitoring to assess safety and functional improvement in gait ability.

Patch 4 Cover FSL Sim Tatoo Adhesive Patch Recall

ANSM recorded safety action R2611097 initiated by Capteur Protect for the Patch 4 Cover FSL Sim Tatoo adhesive patch used with glucose sensors. Users of affected products received notification letters from the company. The recall affects pharmacies, retail chains, and wholesale distributors in France.

MaaT013 Fecal Microbiota Allogeneic Pool Rectal Suspension Recall

ANSM and Clinigen Healthcare France have initiated a precautionary recall of six lots of MaaT013 (fecal microbiota allogeneic pool, rectal suspension). The recall follows discovery of a donor selection process non-compliance where a donor meeting exclusion criteria was included in stool collections used to manufacture the affected lots. Healthcare establishments holding affected lots (7P010/2410111, 7P010/2410092, 7P010/2410096, 7P010/2410109, 7P010/2503009, 7P010/2503012) should quarantine and return product to the manufacturer.

Olympus Gyrus ACMI Everest Cutting Forceps Lot Recall R2607996

ANSM registered safety action R2607996 concerning a lot withdrawal of Everest cutting forceps (pince coupante) manufactured by Olympus Gyrus ACMI. The recall was initiated by Olympus following notification to ANSM. Affected users received a direct communication from the manufacturer. This action targets hospital pharmacies and health establishments that hold the implicated lot.

Boston Scientific Accolade Pacemaker Safety Action - Software Update SMR6

ANSM has published updated safety information regarding Boston Scientific Accolade family implantable pacemakers (Accolade, Proponent, Essentio, Altrua 2, CRT-P Visionist, and Valitude). The agency reports that Boston Scientific is deploying software update SMR6 to correct anomalies in the previous SMR5 update and prevent inappropriate triggering of safety mode. For pace-dependent patients whose devices have not been updated with SMR5 and have 4 years or less of remaining battery life, an appointment should be scheduled without delay. SMR6 may reduce battery longevity for devices with extended longevity (EL) batteries. New device packaging since March 2026 includes information about potentially reduced battery life.

Safety Notice Cryotubes Cryo.s Medical Devices by Greiner Bio-One

ANSM recorded safety action R2609958 concerning Cryotubes Cryo.s medical devices manufactured by Greiner Bio-One. The company has issued a safety communication dated 17/04/2026 to affected users. ANSM directs users to contact Greiner Bio-One directly for details and questions regarding the action.

FDA Removes 12 Peptides from Category 2, Schedules PCAC Review Meetings

FDA announced removal of 12 peptide bulk drug substances from Category 2 of its Section 503A bulk drug substances list, with removal effective approximately April 22, 2026. FDA will convene the Pharmacy Compounding Advisory Committee on July 23–24, 2026, and before the end of February 2027, to discuss whether these peptides should be added to the 503A bulks list. One peptide (GHK-Cu) is also being removed from Category 1 for the same reason.

DOJ Establishes National Fraud Enforcement Division, Consolidates Healthcare and Tax Fraud Enforcement

Acting U.S. Attorney General Todd Blanche announced the creation of the National Fraud Enforcement Division (NFED) on April 7, 2026, consolidating control over the Tax Section, Health Care Fraud Unit, and Market, Government and Consumer Fraud Unit under a new assistant attorney general. The division will centralize case tracking, mandate embedded prosecutors in all U.S. Attorney districts within 21 days, and create a National Fraud Detection Center to proactively identify fraud in taxpayer-funded programs including Medicare and Medicaid. The Civil Division must designate a liaison within 14 days and the Office of Legal Policy must evaluate further realignment within 120 days.

Ohio SB 386 Proposes Replacing MCOs with ASO

Ohio Senators Louis Blessing and Beth Liston introduced Senate Bill 386, the 'Medicaid Savings Act,' proposing to replace the state's seven Medicaid Managed Care Organizations with Administrative Services Organization vendors paid flat fees instead of capitated rates. The bill, currently in Senate Medicaid Committee sponsor testimony, cites Connecticut's ASO transition and potential federal Medicaid cuts under HR1 as rationale.

DOJ Signals Intensifying California Healthcare Fraud Enforcement

DOJ and California Attorney General have intensified healthcare fraud enforcement targeting hospice and home health providers in California. The DOJ announced a $50 million hospice fraud takedown with eight arrests, a $270 million Medi-Cal fraud guilty plea, and AG Bonta dismantled a $267 million hospice fraud scheme with 21 suspects charged. US Attorney Bill Essayli stated this represents the beginning of increased enforcement activity, with additional charges and takedowns expected every few months.

Q1 2026 Hatch-Waxman ANDA Settlements Chart

Robins Kaplan LLP summarizes reported settlements in federal district court Hatch-Waxman ANDA patent litigation cases for Q1 2026. The chart covers 13 settlement summaries involving brand-name drugs including Jardiance, Spravato, Xarelto, Xifaxan, Wakix, and others, documenting case names, patent numbers, and publicly available settlement terms such as consent judgments, injunctions, and dismissal provisions.

Sixth Circuit Holds Tennessee PBM Network and Steering Rules Are ERISA-Preempted

The Sixth Circuit held that Tennessee's PBM laws requiring any-willing-pharmacy access and prohibiting differential copays and steering incentives are ERISA-preempted as applied to self-funded ERISA plans. The court found these laws impermissibly dictate plan structure and administration rather than merely regulating costs. The ruling establishes that employers sponsoring self-funded ERISA plans and their PBMs cannot be compelled to include all willing pharmacies or prohibited from tiered cost-sharing.

California AG Bonta Backs Strict CPOM Rules for MSO-PC Arrangements

California Attorney General Rob Bonta filed an amicus brief in Art Center Holdings v. WCE CA Art, LLC supporting strict interpretation of California's corporate practice of medicine (CPOM) prohibition for MSO-PC arrangements. The brief argues that contractual provisions giving MSOs the unilateral ability to replace physician-owners or control equity transfer create a 'captive PC' and violate CPOM. The filing aligns with S.B. 351 (enacted October 6, 2025), which expands state oversight of private equity and hedge fund involvement in physician practices.

Ohio Senate Bill 109 Sexual Misconduct Policy Changes

Ohio Senate Bill 109 (SB 109), effective March 21, 2025, substantially amends state law to strengthen the State Medical Board of Ohio's authority over licensed healthcare providers. The law shortens reporting timeframes from 60 to 30 days for healthcare facilities, providers, and professional associations; authorizes the Board to summarily suspend licenses for felony charges; requires Board providers on probationary orders to disclose their status to patients; expands criminal code sex offense provisions; and prohibits unauthorized intimate examinations on anesthetized or unconscious patients.

State Medical Board of Ohio Meeting Schedule, March 10-11, 2026

The State Medical Board of Ohio has published its meeting schedule for March 10-11, 2026. The Respiratory Care Advisory Council will meet virtually on March 10 at 2 p.m. On March 11, the Emerging Practice Trends Committee and the Board Meeting will be held in-person at the Rhodes State Office Tower. Meetings are open to the public and will not impose any compliance obligations.

Board Meetings Set for April 2026

The State Medical Board of Ohio has published its April 2026 public meeting schedule. Meetings include the Dietetics Advisory Council (April 6), Quality Assurance Committee, Emerging Practice Trends Committee, Board Meeting, and Compliance Committee (April 8), and the Acupuncture Advisory Council (April 15). Most meetings are in-person at Rhodes State Office Tower; some advisory councils meet virtually.

Monthly Board Meeting Scheduled for May 13, 2026 in Columbus

The State Medical Board of Ohio has scheduled its monthly board meeting for Wednesday, May 13, 2026, at 10:00 AM at the Rhodes State Office Tower, 30 East Broad Street, 3rd Floor, Columbus, OH 43215. The Board comprises twelve members: nine physicians (seven MD, one DO, one DPM) and three non-physician public members, all appointed by the Governor to five-year terms. The meeting is open to the public.

Jonathan Shakesprere Educational Permit #933 Consent Order

The West Virginia Board of Medicine issued a Consent Order against Jonathan Shakesprere's Educational Permit #933 on October 27, 2025. This consent action resolves a disciplinary matter concerning the medical professional's educational permit. Specific terms of the consent order are documented in the linked PDF.

WV Physician Discipline Report 1953-1991

West Virginia Board of Medicine published historical physician discipline records from 1953-1991, listing approximately 100+ cases of disciplinary actions against medical practitioners including podiatrists. The report contains names, case dates, and individual identification numbers for public reference. Cases span from October 1953 through July 1987, with clustering in 1986-1987.

David Mark Anderson MD Hearing Scheduled May 22

The West Virginia Board of Medicine has scheduled a public hearing for David Mark Anderson, MD on May 22, 2026 at 9:30 AM. This is a procedural notice announcing an upcoming administrative hearing. No specific charges or violations are detailed in the notice. Contact the Records Custodian at (304) 558-2921 for additional information.

Methods of Treating Locally Advanced or Metastatic Breast Cancers Using PD-1 Axis Binding Antagonists and Taxanes

The European Patent Office published patent application EP3310815A1, filed by F. Hoffmann-La Roche AG, covering methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists in combination with taxanes. Inventor is Daniel S. Chen. The publication includes IPC classifications covering therapeutic antibodies, antineoplastic compositions, and designated states for national phase entry.

Board of Dentistry Meeting Minutes, 2011-2025

The Hawaii Board of Dentistry has published archived meeting minutes from 2011 through 2025 on its official website. The listing includes regular board meetings and Rules Committee meetings held over the fifteen-year period. The page serves as an administrative archive and does not create any new compliance obligations or regulatory changes.

DIFFRACTIVE INTRAOCULAR LENSES FOR EXTENDED RANGE OF VISION

The European Patent Office publishes Patent EP3595584A1, granted to AMO Groningen B.V., covering diffractive intraocular lenses designed for extended vision range. The invention is classified under A61F 2/16, A61F 2/14, and G02C 7/04. The patent is designated across EU member states and EPO contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Bidirectional Prosthetic Finger with MCP Pivot (EP3785675A2)

The European Patent Office published patent application EP3785675A2, filed by RCM Enterprise, LLC, for a bidirectional prosthetic finger configured for abduction and adduction with MCP pivot. The A2 publication includes the search report and covers the mechanical design of the prosthetic device. The application designates 37 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

Musculoskeletal Injury Evaluation Patent - Sym Healthcare - EP4646998A1

The European Patent Office published patent EP4646998A1, granted to Sym Healthcare Inc., covering a method for evaluating musculoskeletal injuries through 3D dynamic joint range of motion testing and static posture testing for postural abnormalities. The patent was published on April 8, 2026, and provides exclusive rights to the disclosed method.

EP3616212A1 - Click Therapeutics AI Digital Health Patent

The European Patent Office published patent application EP3616212A1 for Click Therapeutics, Inc., covering systems, methods, and apparatuses for managing data in artificial intelligence software and mobile applications for digital health therapeutics. The invention is classified under IPC G16H (Health Informatics) with designations across 31 European states. This patent grant establishes intellectual property rights for AI-driven digital therapeutic technology in European markets.

EP4642324A1 Implantable Medical Device with Code Path Metrics

The European Patent Office published patent application EP4642324A1 for Advanced Neuromodulation Systems, Inc. The invention covers an implantable medical device (IMD) configured to collect and transmit code path metrics data. The application claims priority to multiple IPC classifications including A61N 1/36 (neural stimulation), A61N 1/372 (implantable device control), and G16H 40/40 (health informatics). The patent is designated across 34 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

Nestlé Patent EP3549139A1 for Personalized Nutritional Health Scoring System

The European Patent Office granted Société des Produits Nestlé S.A. Patent EP3549139A1 covering a system and methods for calculating, displaying, modifying, and using improved personalized nutritional health scores to assess and plan optimal diets. The patent application was published on April 8, 2026, with inventor Fabio Mainardi listed. Designated states include AT, BE, DE, DK, ES, FI, FR, GB, GR, and HU among other European countries. The patent is classified under G16H 50/30 and G16H 20/60 (Health Informatics).

IMPLANTABLE MEDICAL DEVICE (IMD) WITH CODE PATH METRICS

The European Patent Office granted European Patent Application EP4642527A1 to Advanced Neuromodulation Systems, Inc. for an implantable medical device with code path metrics. The invention relates to neuromodulation technology that tracks and analyzes software code execution paths within an implanted device. The patent is valid across 44 designated European contracting states.

European Patent Surgical Hub Spatial Awareness

The European Patent Office published patent EP3506292A1 for Ethicon LLC, titled 'Spatial Awareness of Surgical Hubs in Operating Rooms.' The patent, granted April 8, 2026, covers spatial tracking and awareness technologies for surgical hub systems used in medical procedures. The invention is classified under G16H 20/40 and G16H 40/63, relating to health informatics and computer-assisted surgery. The patent designates all major European states including DE, FR, GB, IT, ES, NL, BE, CH, and others.

EP4642325A1 - Implantable Medical Device With Code Path Metrics

The European Patent Office granted Patent EP4642325A1 to Advanced Neuromodulation Systems, Inc. on April 8, 2026. The patent covers an implantable medical device system with code path metrics for neuromodulation applications. The invention relates to the technical fields of medical device monitoring and therapeutic stimulation systems.

Evaluation Method and Device for Comparing Anti-Anxiety Medicine Effects, EP2024168475A1

The European Patent Office published patent application EP2024168475A1 covering an evaluation method and device for comparing anti-anxiety medicine effects with efficiency. The patent is classified under G16H 50/70 (healthcare informatics for diagnosis) and designates all EPO contracting states including AT, BE, CH, DE, DK, ES, FI, FR, GB, IT, NL, NO, PL, PT, SE, and others. The invention provides a systematic method for pharmaceutical researchers to assess and compare the efficacy of different anxiety treatments.

Server Method Cognitive Therapy for Children With Disabilities

The European Patent Office published application EP2024210274A1 on April 8, 2026, covering a server-based cognitive and social therapy system for children with developmental disabilities. The invention uses emotion recognition, gesture analysis, and speech processing to monitor and deliver therapeutic interventions via a mobile application.

Implantable Medical Device Code Path Metrics - EP4642528A1

The EPO published patent application EP4642528A1 for an implantable medical device system that captures code path metrics during device operation, filed by Advanced Neuromodulation Systems, Inc. The application covers neuromodulation devices utilizing machine learning to analyze device performance data. The designated states include all EU member states plus extended countries.

Two Men Charged for Running Fentanyl Lab in Residential Building

DEA New York Division Special Agent in Charge Farhana Islam announced criminal charges against two individuals for narcotics and firearms offenses related to operating an illegal fentanyl manufacturing operation in a residential building. The case involves coordination with the Department of Justice, Homeland Security Investigations, and the Southern District of New York U.S. Attorney's Office.

DNA Editing Using Single-Stranded DNA - EP3303585A1 Patent Grant

The European Patent Office published patent grant EP3303585A1 for DNA editing using single-stranded DNA. The patent names Board of Regents of the University of Nebraska and Tokai University Educational System as applicants. The invention covers biotechnology methods for DNA editing with applications in genetic research and development.

Anti-HER3 Antibody Drug Conjugate Patent by Beijing Sinotau Bio-Pharma

EPO published patent application EP4355787A1 for Anti-HER3 antibody drug conjugate compositions and methods by Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. The patent covers ADC technology targeting HER3 for cancer treatment with designated states spanning major European jurisdictions. Inventors include Zhong Xiaoyan, Li Zhe, and Zhu Jie.

Helix Biopharma Corp. Antibody-Urease Conjugates for Diagnostic and Therapeutic Use

The European Patent Office granted Patent EP2984170A1 to Helix Biopharma Corp. for antibody-urease conjugates for diagnostic and therapeutic purposes. The patent, with inventor Chao Heman, covers compositions classified under A61K 47/68, A61P 35/00, C07K 16/32, C12N 9/80, and C12N 9/96. The designated states include all EU member states and extension countries.

Plants Comprising Wheat G-Type Cytoplasmic Male Sterility Restorer Genes, Molecular Markers and Uses Thereof

The European Patent Office granted BASF SE Patent EP3429334A1 covering wheat plants comprising G-type cytoplasmic male sterility restorer genes and associated molecular markers. The patent is classified under IPC codes A01H, C12N, and C07K, covering biotechnology applications for plant genetics. The designation includes 31 states across the EU and beyond.

Microbial Consortia Patent EP3262151A1, Amvac Chemical Corporation

The European Patent Office published patent application EP3262151A1 titled 'Microbial Consortia' filed by Amvac Chemical Corporation. The patent relates to compositions and methods involving microbial consortia, classified under IPC C12N (microorganisms, fungi, algae), C05F (fertilizers), and A01N (biocides). The patent application designates all EU member states.

Modified Adeno-Associated Virus Capsid Patent EP4389880A1

The European Patent Office published patent application EP4389880A1 for Joint Stock Company Biocad, covering methods of obtaining modified adeno-associated virus (AAV) capsids. The patent is classified under IPC codes C12N 7/00, C12N 15/86, C07K 14/005, and others related to viral vectors and genetic engineering. The patent designates all relevant European contracting states including Germany, France, Italy, Spain, and the United Kingdom.

Microbial Consortia Patent Application EP3262152A1

The European Patent Office published patent application EP3262152A1 for Amvac Chemical Corporation, covering microbial consortia compositions and their applications in agriculture and chemical processing. The patent application includes claims for biological preparations, organic fertilizers, and related compositions. The designated states cover most European countries including DE, FR, GB, ES, IT, NL, and others.

Use of Cellulase to Improve Viscosity Control of Dissolving Pulp

The European Patent Office published patent application EP3365493A1 by Novozymes A/S for the use of cellulase enzymes to improve viscosity control of dissolving pulp. The patent covers methods of treating pulp with cellulase to achieve desired viscosity characteristics in paper manufacturing processes. The application was published April 8, 2026.

City of Hope Patents Phosphorothioated Oligodeoxynucleotide Compounds and Compositions

The European Patent Office published patent application EP3316894A1 for City of Hope covering phosphorothioated oligodeoxynucleotide compounds and pharmaceutical compositions for therapeutic use. The application classifies under IPC codes C12N 15/113 and A61K 31/713 relating to oligonucleotides and nucleic acid preparations. The publication establishes a priority date and makes the application available for opposition.

BASF SE Patents Wheat G-Type Cytoplasmic Male Sterility Restorer Genes

The European Patent Office published patent application EP3429335A1 on April 8, 2026, granting BASF SE exclusive rights to wheat G-type cytoplasmic male sterility restorer genes, molecular markers, and related uses. The patent covers biotechnology applications in plant breeding under IPC classifications C12Q, C07K, C12N, and A01H across all designated EPO member states.

Merthyr Tydfil Children's Services Consultation, Deadline 13 May

Care Inspectorate Wales (CIW) will conduct an assurance check of Merthyr Tydfil County Borough Council Children's Services in May 2026, reviewing the local authority's performance of Social Services duties under relevant legislation. CIW is seeking public feedback from service users by 13 May 2026 via online surveys, and findings will be published on the CIW website.

Three Victorians Arrested, $2M Steroids and Peptides Seized in Joint ABF-TGA Operation

The Australian Border Force and Therapeutic Goods Administration announced the arrest of three Victorians and seizure of over $2 million worth of Performance and Image Enhancing Drugs (PIEDs), including more than 10,000 vials and 600 tablets of steroids and peptide products. The eight-month joint investigation, which began in August 2025 following the interception of 640 vials, led to criminal charges against three individuals for importing Tier 1 Goods (PIEDs). The TGA warned that unapproved peptide products present serious safety risks including contamination, infection, and tissue damage.

Over 30,000 Illegal Vaping Goods Seized in Major TGA Operation, South-West Sydney

The TGA, assisted by NSW Police Force, seized over 30,000 illegal vaping goods from sites in Chipping Norton and Casula on 15 April 2026, with an estimated street value of $1.8 million. This enforcement action follows a significant investigation into unlawful online advertising, supply, and possession of commercial quantities of illegal vaping goods. The TGA warns that non-compliance with vaping offences under the Therapeutic Goods Act 1989 can result in penalties including up to 7 years imprisonment, or fines of up to $2.31 million for individuals and $23.1 million for corporations per offence.

Board of Medical Examiners Full Board Meeting - April 2026

The Montana Board of Medical Examiners has scheduled a full board meeting for April 24, 2026 from 10am to 4pm at 301 S Park Ave, 4th Floor, Large Conference Room. The meeting will be held in-person and virtually via teleconference. New agenda items may be added up to 48 hours before the meeting.

Board Meeting Scheduled for July 24, 2026 in Helena

The Montana Board of Medical Examiners has scheduled a full board meeting for July 24, 2026, from 10am to 4pm at 301 S. Park Ave, Helena (4th Floor Large Conference Room). The meeting will be held in-person and virtually, with teleconference access available for those unable to attend on-site.

Full Board Meeting, Oct 23 2026, Helena

The Montana Board of Medical Examiners announces a full board meeting on October 23, 2026, from 10am to 4pm at 301 S. Park Ave, Helena. The meeting will be held in-person and virtually via Zoom. No regulatory actions or decisions are described in this notice.

Diamond Microelectrodes Neural Interface Patent EP3057499A1

The EPO published patent application EP3057499A1 for microelectrodes made from structured diamond designed for neural interfacing applications. The patent was filed by Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA) with inventors Clément Hebert, Emmanuel Scorsone, Jean-Paul Mazellier, and Lionel Rousseau. The invention covers IPC classifications including A61B 5/24 (measurement of neural or electroencephalographic potentials), A61B 5/291, G01N 27/30, G01N 27/327, H01M 4/04, and H01M 4/02.

Computer-Assisted Surgery System and Method for Calculating a Distance with Inertial Sensors

The European Patent Office published patent application EP3518805A1 for Orthosoft ULC, covering a computer-assisted surgery system and method that calculates distances using inertial sensors. The invention includes five named inventors and is classified under A61B (diagnosis, surgery, measurement). The patent designates all relevant EU member states for protection.

Electrode Array for Physiological Monitoring Device

The European Patent Office published patent application EP3242593A1 for Medasense Biometrics Ltd., covering an electrode array for physiological monitoring and associated devices. The patent application includes IPC classifications related to vital sign measurement, electrode arrangements, and signal processing for physiological data. The designated contracting states span most EU member states plus other European countries.

Nanoleq AG Physiological Monitoring and Personalized Breathing Exercise Patent

The European Patent Office published patent application EP4426191A1 for Nanoleq AG, covering a system and method for monitoring a user's physiological state and providing personalized breathing exercises. The application names six inventors including Serge Weydert and Vincent Martinez and classifies under IPC codes A61B for diagnostic and measurement devices.

Selection of a Preferred Intraocular Lens Based on Ray Tracing

The EPO published patent application EP4258972A1 for Alcon Inc., titled 'Selection of a Preferred Intraocular Lens Based on Ray Tracing.' The invention relates to methods for selecting intraocular lenses (IOLs) for cataract surgery using ray tracing optical calculations to predict post-operative visual outcomes. The patent designates 37 European states including major markets such as DE, FR, GB, IT, ES, and NL.

Neurent Medical Nasal Treatment Patent Application

The European Patent Office published patent application EP4225185A1 filed by Neurent Medical Limited for systems and methods of therapeutic nasal treatment. The application was filed by inventor David Townley with designated states covering the EU and EPC contracting states. This publication makes the application publicly available for examination and opposition.

System and Method for Identification of Biological Tissues

The European Patent Office granted patent EP3285059A1 to Micromass UK Limited on April 8, 2026, covering a system and method for identifying biological tissues using mass spectrometry. The patent (Inventor: Zoltán Takáts) applies across 38 designated European states including Germany, France, the United Kingdom, Italy, and Spain.

FUJIFILM Medical Drug Recognition Device, Method, Program

The European Patent Office granted Patent EP3603604A1 to FUJIFILM Medical Co., Ltd. for a drug recognition device, method, and program. The invention uses computer vision (G06V) and health informatics (G16H) technologies to identify and analyze drugs. The patent covers designated contracting states across the European Union.

Anonymous Interactive Display System with Extended Timeout Period

The European Patent Office published HeartFlow, Inc.'s European patent application EP3676853A1 for systems and methods generating anonymous interactive displays with extended timeout periods. The patent application (IPC G16H 40/60, G16H 10/60) covers health informatics technology for medical imaging diagnostics. The application designates 35 European states including Germany, France, United Kingdom, Italy, Spain, Netherlands, and Switzerland.

EP3635741A1 Controls for Robot-Assisted Surgical Platforms

EPO granted European Patent EP3635741A1 to Ethicon LLC on April 8, 2026, covering controls for robot-assisted surgical platforms. The patent lists inventors Frederick E. Shelton IV, David C. Yates, and Jason L. Harris, with IPC classifications including G16H (Health Informatics) and A61B (Medical/Surgery). The patent is designated for all 31 European states including Germany, France, the United Kingdom, Italy, and Spain.

Sony Medical System, Medical Apparatus, and Medical Method Patent - EP3844772A1

The European Patent Office published patent EP3844772A1 for Sony Group Corporation, covering a medical system, medical apparatus, and medical method classified under G16H (Health Informatics). The patent names five inventors and grants Sony exclusive rights to the claimed medical technology across all designated EU member states and associated territories.

Apple Patent on Medical Term Search, Published Apr 8th

Apple Patent on Medical Term Search, Published Apr 8th

Study Data Technical Conformance Guide Technical Specifications Document

FDA issued technical specifications for study data conformance to guide sponsors and applicants on formatting study data submissions for drug and biologics regulatory review. The guidance applies to regulated product submissions under FDA jurisdiction. It represents current FDA thinking on technical data standards without creating new legal obligations.

NC Officials Testify Before Legislature on Medicaid Fraud Prevention

NCDHHS Secretary Dev Sangvai and Attorney General Jeff Jackson testified before the NC General Assembly House Select Committee on Oversight and Reform on April 16, 2026, regarding Medicaid fraud prevention efforts. NC Medicaid covers over 3 million North Carolinians (1 in 4 residents) with a 0.46% eligibility error rate. In 2025, the program reported 158 credible allegations of member fraud and 228 credible allegations of provider fraud among 114,454 enrolled providers. The Attorney General's Medicaid Investigations Division has recovered over $1.2 billion in restitution and penalties for North Carolina.

PREP Performance Measures Information Collection

The Administration for Children and Families (ACF) published a notice announcing a proposed information collection activity for the Personal Responsibility Education Program (PREP) Performance Measures. The notice opens a 60-day public comment period through June 16, 2026. This information collection supports monitoring of state and territorial PREP program performance outcomes.

FDA ANDA and 505(b)(2) Approvals - First Quarter 2026

JD Supra Healthcare published a compilation tracking FDA Abbreviated New Drug Application and 505(b)(2) Application approvals for Q1 2026 (January through late March). The chart lists over 100 final generic drug approvals, including approval dates, reference-listed drugs, generic drug names, NDA holders, ANDA applicants, and ANDA numbers. Companies represented include Taro, Glenmark, Sandoz, Amneal, Apotex, Zydus, and numerous other generic manufacturers.

Authorization of Emergency Use for Four Animal Drugs for Treatment of New World Screwworm

FDA announced the issuance of four Emergency Use Authorizations (EUAs) for animal drugs to treat New World screwworm infestations in livestock and companion animals. Three EUAs were issued to Boehringer Ingelheim Animal Health USA for prevention and treatment in cattle, dogs, and cats. One EUA was issued to Health and Hygiene (Pty) Ltd. for use in cattle, horses, sheep, goats, deer, birds, and captive wild mammals. The EUAs were effective on February 5, February 18, and March 10, 2026, following an August 2025 HHS determination of significant public health emergency potential.

Radioactive Drug Research Committees Information Collection

The FDA is soliciting public comments on an extension of existing information collection requirements related to Radioactive Drug Research Committees under 21 CFR 361.1. Under the Paperwork Reduction Act, the Agency must publish notice and allow 60 days for public comment before submitting the collection to OMB for approval. Comments are being sought on whether the proposed collection of information is necessary for proper FDA functions.

Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed

The FDA is announcing an opportunity for public comment on a proposed extension of its generic clearance for qualitative data collection. The collection supports social and behavioral research for food, dietary supplements, cosmetics, and animal food and feed. Under the Paperwork Reduction Act, the Agency must publish a 60-day notice and allow public comment before submitting the collection to OMB. Comments are due by June 16, 2026.

Animal Generic Drug User Fee Act Public Meeting Request for Comments

The FDA announced a virtual public meeting on May 27, 2026 (11 a.m. to 1 p.m. ET) to gather stakeholder input on the Animal Generic Drug User Fee Act (AGDUFA) reauthorization. The docket (FDA-2011-N-0655) will remain open for comments through December 1, 2027, with comments for website publication due by July 1, 2026. This notice solicits feedback from the generic animal drug industry on program improvements.

Animal Drug User Fee Act; Public Meeting; Request for Comments

The FDA announced a virtual public meeting on the Animal Drug User Fee Act (ADUFA) reauthorization process. The meeting will be held May 27, 2026, from 2 p.m. to 4 p.m. Eastern Time. The docket will remain open for comments until December 1, 2027, with comments suggesting program changes due by July 1, 2026 for publication on the FDA website.

Verily Life Sciences LLC - Pattern Discovery in Continuous Glucose Monitoring Data

USPTO granted patent US12588838B1 to Verily Life Sciences LLC on March 31, 2026. The patent covers diabetes management platforms that apply similarity algorithms, including dynamic time warping, to glucose measurement data series to discover patterns indicative of similar behaviors and circumstances. The patent contains 20 claims and was filed on September 18, 2020.

Walmart Apollo AI Symptom Checker Patent, Granted 14th Apr

Walmart Apollo AI Symptom Checker Patent, Granted 14th Apr

Apparatus and Methods for Supporting Medical Decisions

The USPTO granted patent US12603178B2 to Kyung Hee University's Industry Cooperation Group for an AI-powered medical decision support apparatus and methods. The patent covers a visual-linguistic neural learning system with cause mining, logical reasoning, and proof inference capabilities for analyzing medical images and generating reports. The patent claims include 14 items across multiple CPC classifications including G16H medical informatics categories.

System and Method for Providing Dental Services to a Patient

Dental Patient Digital Scanning Interface Patent Granted

Optum Patent for Dynamic Health Appointment Scheduling Using Real-Time Health Conditions

USPTO granted Patent US12603183B2 to Optum, Inc. covering systems and methods for scheduling healthcare appointments dynamically based on real-time health conditions. The patent claims 17 total claims and was filed on October 7, 2022. The technology uses machine learning to identify similar health profiles, generate appointment schedules, evaluate risk scores, and adjust scheduling based on changes in user health data.

US12603184B2 - Systems and Methods for Continuous Cancer Treatment and Prognostics

USPTO granted patent US12603184B2 to The Regents of the University of California on April 14, 2026. The patent covers AI systems for continuous cancer treatment and prognostics, including methods for organizing multimodal health data, assessing data quality, and applying NLP to electronic health records for cancer survival prediction. The patent contains 17 claims and falls under CPC classifications G16H 50/30, G16H 10/60, and related health informatics categories.

Scientific Clinical Diffusion Network

USPTO granted patent US12603185B1 to IQVIA Inc. covering methods and systems for generating heterogeneous networks that connect clinical healthcare provider networks with scientific researcher networks. The patent includes 20 claims and covers techniques for predicting cross-network links and identifying clinical and scientific leaders through graph-based analysis. The invention applies to health informatics analytics platforms that integrate clinical and scientific evidence.

Net Energy Model for Companion Animals and Methods

USPTO granted patent US12588690B2 to Mars, Incorporated covering a net energy prediction model for companion animal pet foods. The patent includes methods for determining appropriate feeding amounts, providing feeding guidelines, and methods of maintaining desired weight or effecting weight loss in companion animals. The patent contains 3 claims and was filed on May 9, 2019.

UNLOXCYT Patent Extension Determination Comment Period

FDA has opened a public comment period regarding the patent extension determination for UNLOXCYT (a pharmaceutical drug product). Stakeholders may submit comments through the Regulations.gov portal. The comment form collects commenter identity, email address for confirmation, and optional attachments up to 20 files.

P230025 Safety Effectiveness Data Summary

FDA issued a Final Order for Premarket Approval application P230025, summarizing the safety and effectiveness data reviewed for the medical device. The order documents FDA's determination that the device meets approval standards based on clinical and bench testing data submitted by the sponsor. This final order concludes the premarket review process for the device.

FDA Reclassifies Non-Invasive Bone Growth Stimulators to Class II

FDA issued a final order reclassifying non-invasive bone growth stimulators (product codes LOF and LPQ) from class III to class II, subject to premarket notification (510(k)) and special controls. The devices, previously requiring premarket approval (PMA), are now subject to the less burdensome 510(k) pathway. The reclassification is effective May 18, 2026.

Stability Testing for Medicated Premixes Draft Guidance

FDA's Center for Veterinary Medicine (CVM) published draft guidance revising VICH GL8(R), updating stability testing requirements for medicated premixes used in veterinary medicine. The document is open for public comment through June 15. This guidance aligns U.S. requirements with international VICH harmonized standards for veterinary pharmaceutical products.

Stability Testing Medicated Premixes Draft Guidance

FDA has issued draft guidance on stability testing requirements for medicated premixes, opening a public comment period. The guidance applies to veterinary pharmaceutical manufacturers producing medicated feed premixes. Interested parties may submit comments through Regulations.gov. The docket number is FDA-2021-D-0613-0003.

FDA CTP Complaint Filed April 16, 2026

FDA's Center for Tobacco Products (CTP) filed a complaint on April 16, 2026, initiating formal enforcement proceedings against undisclosed parties for alleged violations of tobacco regulations under the Federal Food, Drug, and Cosmetic Act. The complaint, docketed as FDA-2026-H-3940-0001, is available on Regulations.gov with supporting documentation. This enforcement action may result in civil penalties, injunctive relief, or other remedies as determined through the administrative or judicial process.

UNLOXCYT Regulatory Review Period; Comment by Jun 15

UNLOXCYT Regulatory Review Period; Comment by Jun 15

P210016 Safety Effectiveness Summary

FDA issued a Final Order for Premarket Approval P210016, including a Safety Effectiveness Summary for the Class III medical device. This order completes the FDA premarket approval review process, authorizing the device for market entry based on demonstrated safety and effectiveness data. The order applies to the device manufacturer holding PMA P210016.

Tumor Stroma Imaging Agent with FAP Targeting

USPTO granted patent US12599685B2 to Shanghai University of Medicine & Health Sciences for a tumor stroma imaging agent targeting fibroblast activation protein (FAP). The imaging agent exhibits high affinity for FAP, high uptake for malignant tumors with high FAP expression, and high sensitivity and specificity for tumor diagnosis. The patent covers the chemical structure where R is hydrogen or fluorine, and claims the agent's use for malignant tumor diagnosis and treatment with prolonged half-life.

Antibody for Binding to Interleukin 4 Receptor

USPTO granted Patent US12600771B2 to Connect Biopharma Hong Kong Limited for an antibody capable of binding to the interleukin 4 (IL-4) receptor. The patent covers the antibody itself, encoding nucleic acids, vectors, host cells, production methods, medical uses, and kits. The patent contains 30 claims and was filed on November 15, 2023.

Serum Exosome With High Osteogenesis and High Angiogenesis for Bone Defect Repair

USPTO granted Patent US12599630B2 to Peking University School and Hospital of Stomatology for a serum exosome composition with high osteogenesis and high angiogenesis for bone defect repair. The patent covers exosomes derived from serum during fracture recovery period (weeks 2-5 post-fracture) and methods of preparing and using them for bone defect repair. The patent contains 5 claims.

Megmilk Snow Brand - US12599639B2 Joint Function-Improving Composition Patent

USPTO granted patent US12599639B2 to MEGMILK SNOW BRAND CO., LTD. for a joint function-improving composition containing bacterial cells and/or cultures of Lactobacillus, Lactococcus, Streptococcus, or Bifidobacterium genera combined with a joint function-improving agent. The composition targets prevention or treatment of osteoarthritis and rheumatoid arthritis through chondrocyte growth promotion and suppression of inflammation, cartilage degradation, pain, and neuronal outgrowth factors. The patent covers food, drink, feed, and pharmaceutical applications.

CAR T Cell Therapy Patent - US12600775B2

USPTO granted Patent US12600775B2 to Kite Pharma, Inc. for methods of preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy and their use in cell therapy. The patent covers CAR T cell therapy methods with applications in cancer treatment.

Systems and Methods for Generating Nitric Oxide Using Microwave Energy (EP4384248A1)

The European Patent Office granted Patent EP4384248A1 to Third Pole, Inc. covering systems and methods for generating nitric oxide using microwave energy. The patent application includes multiple IPC classifications spanning medical devices, chemical compositions, and plasma generation technologies. The patent designates 31 European contracting states for protection.

Device for Delivering Substance to Body Cavity - EP4243993A1

The European Patent Office published patent application EP4243993A1 for AptarGroup, Inc., covering devices for delivering a substance to a body cavity. The invention relates to nasal spray applicators and substance delivery mechanisms classified under IPC A61M. The patent application was published April 8, 2026, designating all EU member states and extended European Patent Convention states.

EP4251259A1, Bulkhead Anchor Medical Leads

The European Patent Office published patent application EP4251259A1 titled 'Bulkhead Anchor for Medical Device Leads' on April 8, 2026. The application names Advanced Neuromodulation Systems, Inc. as the applicant with inventors Dawson, Jackson, Raines, and Reardon. The invention relates to anchoring mechanisms for neurostimulation and catheter leads classified under A61N 1/05, A61M 25/04, and A61B 17/00.

Guidewire Extension System for Catheter Placement Device

The European Patent Office published patent application EP4115938A1 for a guidewire extension system used in catheter placement devices, filed by C. R. Bard, Inc. The invention relates to medical device technology for improving catheter placement procedures. The patent grants IP rights across 38 designated European states including AT, BE, DE, ES, FR, GB, IT, NL, and others.

Inreda Diabetic Infusion Set With Adjustable Elements

The European Patent Office published patent EP4319860A1 for Inreda Diabetic B.V., covering an adjustable infusion set system for diabetic patients. The patent designates all EU member states as well as other European countries including Switzerland, Norway, Iceland, and Turkey.

Adipose Tissue Purification Machine, Neosyad

The European Patent Office published patent EP4444375A1 for Neosyad, covering a machine for purifying adipose tissue and reintroducing it into a patient's body. The patent names inventors Roche, Cabaud, and Nelissen and classifies under A61M medical devices.

Peritoneal Dialysis Fluid Preparation Systems and Methods - EP4218849A2

The European Patent Office published European patent application EP4218849A2 by Gambro Lundia AB, covering systems and methods for peritoneal dialysis having point-of-use dialysis fluid preparation including mixing and heating. The application, filed under IPC classification A61M 1/28, names nine inventors and is now publicly available in all designated contracting states. The publication grants the applicant exclusive rights to the disclosed technology.

Chemical Engines and Methods for Injecting Highly Viscous Fluids - Eli Lilly EP4252801A2

The European Patent Office published patent application EP4252801A2 for Eli Lilly and Company, titled 'Chemical Engines and Methods for Their Use, Especially in the Injection of Highly Viscous Fluids.' The patent covers injection devices designed to deliver highly viscous pharmaceutical fluids, classified under A61M (medical injectors). The patent designates all EU member states and EPO contracting states.

Status Sensing Systems for Connected Injection Device EP4257167A2

EPO published patent application EP4257167A2 for Eli Lilly and Company's status sensing systems for connected injection devices. The application, filed by inventors PATEL, SOMLAI, and WIESLER, covers injection devices with sensing technology for monitoring injection status. The patent designates all EU member states plus extension states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.

Chimeric Antigen Receptors Targeting CD79B and CD19 for Cancer Treatment

USPTO granted Patent US12600760B2 to The General Hospital Corporation on April 14, 2026, covering chimeric antigen receptors (CARs) targeting CD79B and CD19 for cancer treatment. The patent includes methods for producing T cells with CARs having extracellular domains that bind both CD79b and CD19. Invented by Marcela V. Maus, the patent covers upfront treatment methods where the patient has not been previously treated for the cancer.

Treatments for Ocular Neovascularization

USPTO granted patent US12599680B1 to 4D Molecular Therapeutics Inc. covering compositions and methods for treating ocular neovascular diseases such as wet age-related macular degeneration. The patent contains 24 claims and expires August 14, 2045.

September 2025 Nursing Board Disciplinary Actions Published

The Oklahoma Board of Nursing Investigative Division published September 2025 Board Actions documents containing disciplinary actions against licensed nurses. Both PDF and Excel formats of the disciplinary actions data are now available on the Oklahoma government website. Healthcare providers and legal professionals should review these documents for compliance implications.

Rabid Bat Confirmed in Lexington County One Person and One Pet Exposed

South Carolina DPH confirmed a bat found near Henslowe and Ashburton lanes in West Columbia tested positive for rabies on April 14, 2026, after being submitted for testing on April 13. One person was potentially exposed and has been referred to their health care provider, while one dog was exposed and will be quarantined under the South Carolina Rabies Control Act. This is the 23rd case of rabid animals statewide in 2026 and the second in Lexington County.

Rabid Dog Confirmed in Anderson County; Four People and One Pet Exposed

The South Carolina Department of Public Health confirmed a brown and black German shepherd dog found near La Paz Street and Los Cabos Lane in Pendleton tested positive for rabies on April 15, 2026. Four people were exposed and have been referred to healthcare providers. One dog was exposed and will be quarantined per the South Carolina Rabies Control Act. This is the fifth animal to test positive for rabies in Anderson County in 2026, with 24 cases statewide.

Evaluation of the PATH Program—Reinstatement of Information Collection

SAMHSA published a notice announcing the reinstatement of information collection activities for the Evaluation of the Projects for Assistance in Transition From Homelessness (PATH) Program. The notice requests public comments on proposed data collection instruments including a State PATH Contact (SPC) Web Survey (reduced from 82 to 49 questions) and Site Visit Discussion Guides. The estimated total burden is 578.5 hours across 361 respondents with a total hour cost of $15,896.39. Comments are due within 60 days of publication.

Boil Water Advisory Issued for Jefferson Co RWD 7, Jefferson County, Kansas

KDHE has issued a boil water advisory for Jefferson Co RWD 7 public water supply system in Jefferson County, Kansas, effective April 16, 2026. The advisory was issued due to a waterline break resulting in loss of pressure in the distribution system, which creates risk of bacterial contamination and loss of chlorine residuals. Customers should boil water for one minute before drinking or use bottled water until KDHE rescinds the advisory following laboratory testing.

Air Quality Health Advisory Issued for Flint Hills Prescribed Burns

The Kansas Department of Health and Environment issued an Air Quality Health Advisory on April 16, 2026, due to elevated Air Quality Index values from prescribed burns across the Flint Hills. Increased burning activity on April 15 resulted in elevated AQI readings this morning, with winds expected to carry additional smoke from ongoing burns. KDHE and partners continue implementing the Flint Hills Smoke Management Plan to mitigate air quality impacts.

Early Alert: American Contract Systems Coronary Angio Pack Convenience Kits with Affected Namic RA Syringes

FDA's Center for Devices and Radiological Health (CDRH) issued an Early Alert for American Contract Systems Coronary Angio Pack convenience kits (ANCA80AQ, ANCA80AP) containing Namic Angiographic Control Syringes with Rotating Adaptor subject to Medline's recall. The syringes' rotating adaptor may unwind during use, causing loose connections or disconnection between syringe and manifold. This poses risks of biohazard exposure, blood loss, infection, air embolism, serious injury, or death. Four serious injuries have been reported as of March 13.

Thiocycloheptyne Derivatives and Their Use

The EPO published European patent application EP3820858A1 for thiocycloheptyne derivatives and their pharmaceutical use, filed by Cristal Delivery B.V. The patent covers thiocycloheptyne compound compositions and their therapeutic applications under IPC classification A61K. The patent is validated in all designated EU contracting states including Germany, France, the United Kingdom, Italy, Spain, and 24 other jurisdictions.

Phosphoantigen Prodrug Compounds

The European Patent Office granted patent EP3818064A1 for phosphoantigen prodrug compounds to University College Cardiff Consultants Ltd. and University of Birmingham. The patent covers novel chemical compounds with applications in immunology and oncology, classified under IPC C07F 9/44 and A61K 31/664. The patent is valid in 44 designated contracting states across Europe.

TNF Inhibitor for Gastrointestinal Disease Treatment, EP3810095A1

The EPO published patent application EP3810095A1 for BT Bidco, Inc., covering a TNF inhibitor formulation for treating gastrointestinal diseases. The patent application was published under IPC classifications A61K 9/22, A61K 31/436, and A61K 48/00. The application designates all EU member states plus other EPC contracting states including CH, GB, LI, MC, NO, TR, and IS.

Hydrocortisone for Treatment of Mastitis in Non-Human Mammals, EP3829591A1

The European Patent Office published Patent Application EP3829591A1 for VIRBAC covering hydrocortisone formulations for treating mastitis in non-human mammals. The application names inventors HAVRILECK Bertrand, JASMIN Pierre, and MCGAHIE David with IPC classifications in A61K therapeutic preparations. The designated states cover EU contracting states including AT, BE, DE, ES, FR, GB, IT, NL, PL, and others.

Compounds, Compositions, Methods, and Uses for Treating Cancer and Immunological Disorders

The European Patent Office granted Patent EP3820533A2 to IL-2RX, Inc. covering novel compounds and compositions for treating cancer and immunological disorders. The patent application, filed by inventors Soares and Hurt, was published April 8, 2026 under IPC classifications A61K 47/64, A61K 47/65, A61P 35/00, and A61P 37/02. The patent is designated for all EU member states and extended territories.

PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr

PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr

Biotech Insights - Spring 2026

Haynes Boone published its Spring 2026 biotech regulatory update covering FDA post-approval change requirements for New Drug Applications and a Federal Circuit patent eligibility ruling. The article explains that NDA changes are categorized as major (prior FDA approval required), moderate (30 days after supplement filing), or minor (annual report only), with dosage form changes typically requiring a new NDA. The piece also analyzes the Federal Circuit's decision in REGENXBIO v. Sarepta upholding patent eligibility for engineered host cells containing heterologous non-AAV sequences.

LEAD Model Features, Five Legal Issues for ACOs

K&L Gates LLP published a primer on the Long Term Enhanced ACO Design (LEAD) Model, outlining its key features and five legal considerations for Accountable Care Organizations and providers evaluating participation. The article provides background on the model and discusses implications for accountable care arrangements under Medicare.

FDA Encourages Sponsors to Pursue New Testosterone Therapy Indication for Low Libido

The FDA announced it is taking an initial step to expand treatment options for men with low libido by encouraging sponsors of approved testosterone replacement therapy (TRT) products to express interest in pursuing a potential new indication for idiopathic hypogonadism. Following a preliminary review of published clinical literature and a December 2025 expert panel discussion, FDA identified data suggesting TRT may be safe and effective for certain men with low libido related to low testosterone without an identifiable cause.

Phase 1 Pomalidomide After CAR T-Cell Therapy for Relapsed or Refractory CD19+ B-Cell Leukemia or Lymphoma

The NIH National Library of Medicine registered Phase 1 clinical trial NCT07532525 to evaluate pomalidomide following CD19 CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma. The single-arm trial will assess safety and preliminary effectiveness of the combination therapy in approximately 24 participants.

Chemogenetic Gene Therapy for Parkinson's Disease Using AAV Virus and Stereotactic Surgery

NIH registered a Phase 1 clinical trial (NCT07533591) evaluating a chemogenetic gene therapy called STP-001 for Parkinson's disease. The therapy uses an AAV viral vector with hM4Di chemogenetic effector delivered via stereotactic surgery to the subthalamic nucleus, combined with clozapine to modulate neuronal activity. The study aims to improve core motor symptoms in PD patients.

Real-Time MAP Forecasts, Cesarean Delivery Pilot Study

NIH's ClinicalTrials.gov registered a single-center, open-label pilot study (NCT07534774) evaluating a real-time maternal mean arterial pressure (MAP) decision-support algorithm during elective cesarean delivery under spinal anesthesia. The clinician-facing display provides 1-, 2-, and 3-minute MAP forecasts from spinal anesthesia administration until delivery or up to 20 minutes. Clinicians retain full autonomy over treatment decisions with no dosing recommendations provided. Primary outcome is prospective accuracy of short-horizon MAP forecasts; secondary outcomes assess intraoperative hypotension burden and phenylephrine exposure.

Novel Hollow Cusp Fracture Reducer Clinical Evaluation

NIH ClinicalTrials.gov registered and published results from a prospective randomized controlled trial (NCT07534904) conducted at Hanzhong Central Hospital between January 2020 and January 2023, evaluating a novel hollow cusp fracture reducer device against conventional manual reduction in 142 patients with femoral shaft and patellar fractures. The device group showed significantly reduced operative time and intraoperative fluoroscopy frequency, improved K-wire placement accuracy, and accelerated fracture healing compared to conventional techniques.

EIT Pilot Study Tests Perfusion and Ventilation Distribution in Children

The NIH has registered a new pilot study (NCT07532811) on ClinicalTrials.gov evaluating the feasibility of assessing pulmonary perfusion in children using electrical impedance tomography (EIT) with a weight-adjusted hypertonic saline bolus. The study addresses a gap in pediatric protocols, as existing adult perfusion assessment methods using 10 mL of 7.5-10% NaCl are unsuitable for small children. The single-center study targets children with acute respiratory failure.

Elecoglipron and Statins PK Study Phase 1 in Healthy Participants

NIH registered a Phase 1 clinical trial (NCT07534592) to investigate pharmacokinetic interactions between elecoglipron and statins (atorvastatin and rosuvastatin) in healthy participants. The single-center study will enroll participants in two groups to assess co-administration effects. Elecoglipron is an investigational drug not yet approved by FDA.

Effects of 7-Day Creatine Supplementation on Cognitive Function After High-Intensity Interval Training in Active Young Men

NIH ClinicalTrials.gov registered a new clinical trial (NCT07534293) to evaluate whether 7-day creatine monohydrate supplementation affects cognitive function after high-intensity interval training in active young men. The randomized controlled trial will enroll 20 participants across four groups receiving placebo or creatine at 0.1 or 0.3 g/KgBW/day, with or without exercise, measuring outcomes via visual reaction time and Trail Making Tests. The trial is listed as Not Yet Recruiting with an anticipated completion date of April 16, 2026.

Phase 1 CD19 CAR-γδ T Cells for Relapsed/Refractory Autoimmune Nephropathy

NIH registered a Phase 1 clinical trial (NCT07535138) evaluating CD19 CAR-γδ T cell therapy for patients with relapsed/refractory autoimmune nephropathy, including lupus nephritis, IgA nephropathy, and membranous nephropathy. The single-arm, single-center, open-label dose-escalation study will use a 3+3 design to assess safety, tolerability, recommended dose, and maximum tolerated dose over a 1-year follow-up period.

Impact of Atypical Swallowing on Periodontal Health in Adults

The NIH ClinicalTrials.gov registry has posted NCT07534306, an observational study examining the prevalence of atypical (dysfunctional) swallowing in adults with periodontitis. The study will investigate correlations between abnormal tongue thrust patterns and clinical oral manifestations including dental mobility and periodontal deterioration. Researchers will collect data through patient questionnaires and clinical evaluations to assess how incorrect lingual posture affects tooth-supporting tissues.

Orthodontic and Articular Effects of the One-Step No-Prep Protocol

NIH's ClinicalTrials.gov registered a new observational study (NCT07533240) investigating the One-Step No-Prep protocol for treating localized tooth wear in adults. The study will evaluate orthodontic tooth movements, temporomandibular joint function, and restoration stability using digital scans, 3D imaging, and jaw-tracking. Participants will receive bonded restorations combined with orthodontic mechanics and complete questionnaires on comfort and satisfaction.

ConvaTec Limited Catheter Medical Device Patent B2

The USPTO granted US Patent 12594399B2 to ConvaTec Limited on April 7, 2026, covering a catheter medical device. The patent discloses a tubular body portion with a proximal and distal end and a cuff mounted to the distal end portion. Assignee: ConvaTec Limited. Inventors: Mingliang Lawrence Tsai and Pavel Zeliankevich. The patent contains 20 claims under CPC classification A61M.

RESMED Vent System Patient Interface Patent Granted

USPTO granted patent US12594397B2 to ResMed Pty Ltd on April 7, 2026, covering a vent system for patient interface used in CPAP/BiPAP mask ventilation. The patent describes a vent housing with an inlet, outlet, exhaust gas orifice, and an elastically deformable moveable membrane that responds to pressure differences to regulate exhaust gas flow. The patent contains 46 claims and has a filing date of February 26, 2020.

Guide Wire with Pseudoelastic Core Shaft and Auxiliary Wire - US12594404B2

USPTO granted patent US12594404B2 to ASAHI INTECC CO., LTD. for a guide wire featuring a core shaft with a pseudoelastic distal end portion and an auxiliary wire arranged parallel to the distal end portion, having high flexibility and breaking strength. The patent, assigned 4 claims, covers inventions by Keisuke Ushida and Masahiro Kashiwai.

Serration Balloon Medical Device Patent Granted to Cagent Vascular

USPTO granted patent US12594406B2 to Cagent Vascular, Inc. for a serration balloon medical device. The invention comprises longitudinally extending members with periodic raised wedges attached to an angioplasty balloon via fiber coating or polymer matrix bonding. The patent includes 22 claims and was filed on June 1, 2023.

Mayor Bowser Announces 21st Emancipation Day Celebration, New Location

Mayor Muriel Bowser announces the 21st annual DC Emancipation Day celebration on Sunday, April 19, 2026. The event moves to a new location at 13th Street and Pennsylvania Avenue NW. The free day-long celebration includes a festival, parade, and star-studded concert featuring T.I., Mýa, and Tye Tribbett. DC Emancipation Day commemorates the 1862 signing of the DC Compensated Emancipation Act, which freed more than 3,100 enslaved people.

Delivery System with Torqueable Catheter Shaft

USPTO granted Patent US12594400B2 to Medtronic, Inc. on April 7, 2026. The patent covers a delivery system with a torqueable catheter shaft design featuring multiple polymer layers with varying stiffness, tubular braid components, and hypotube configurations for improved torque transmission. The patent contains 20 claims.

Catheter with Serially Connected Sensing Structures and Methods of Calibration and Detection

USPTO granted Patent US12594402B2 to Biosense Webster (Israel) Ltd. covering catheters with serially connected position and pressure sensing coils designed to reduce lead breakage and failure. The patent includes methods for calibration, position/pressure sensing, and detecting magnetic field interference between catheters or metal objects using dual sensor signals as an error-check mechanism.

Bard Access Introducer Assembly Patent, 17 Claims

USPTO granted Patent US12594403B2 to Bard Access Systems, Inc. on April 7, 2026. The patent covers introducer components, assemblies, and methods including an access guidewire loaded in a needle assembly with a valve mechanism. The patent contains 17 claims and has a filing date of August 24, 2022.

US12594407B2 - Multi-Needle Preparation Delivery Device Patent Granted to Beijing Boe Technology

The USPTO granted patent US12594407B2 to Beijing Boe Technology Development Co., Ltd. on April 7, 2026, covering a preparation delivery assembly and device with multiple needles of varying lengths. The patent includes 15 claims and is classified under A61M medical device categories. The invention features a dual-substrate design with channels and chambers for controlled delivery of preparations through needles of different lengths.

Surgical Instrument Ports for Wound Retractors (US12594408B2)

The USPTO granted patent US12594408B2 to Intuitive Surgical Operations, Inc. for surgical instrument ports configured for use with wound retractors. The patent covers ports with channels to receive surgical instrument cannulas and lateral walls for engagement with wound retractor end portions. The patent has 22 claims and inventors include Brian M. Crews, Sam Crews, Craig R. Gerbi, Michael Hurst, and Sumona Adhya.

US12594409B2 - Surgical Port Sleeve with Reversibly Radially Expandable Flanges

USPTO granted Patent US12594409B2 to University Hospitals Cleveland Medical Center on April 7, 2026, covering a sleeve for retention of a surgical port with reversibly radially expandable flanges. The patent claims a first sleeve portion, a second reversibly slidable sleeve portion, a plurality of radially expandable flanges, and a reversible locking mechanism. The patent contains 13 claims and was filed on April 3, 2024 under Application No. 18853697.

ICU Medical Patent, Antimicrobial Delivery Device for Medical Device Connections

USPTO granted patent US12594410B2 to ICU Medical, Inc. for a device that delivers antimicrobial composition into medical device connections. The device comprises a male connector with a recess containing chlorhexidine acetate at the distal tip to prevent infection and microbial ingress. The patent includes 20 claims.

US12594411B2 - Apparatus and Method for Joining Metal Sleeve onto Tube for Catheters

USPTO granted patent US12594411B2 to Best Medical International, Inc. covering an apparatus and process for joining metal or ceramic sleeves onto flexible tubular members for catheter applications. The invention uses friction-based material joining with rotational heating to create integral seals. The patent protects the assignee's manufacturing process for medical catheters and flexi needles.

Sound Masking System for Respiratory Device, ResMed

USPTO granted Patent US12594398B2 to ResMed Sensor Technologies Limited for a sound masking system that detects air leaks from respiratory masks and emits masking sounds. The system includes a microphone, speaker, and control system to analyze audio data and determine if mask leakage noise is occurring, then triggers sound emission to mask the noise. The patent contains 20 claims and was filed on October 4, 2022.

Flush Syringe with Multiple Scrubbing Devices - US12594412B2

The USPTO granted patent US12594412B2 to Becton, Dickinson and Company for an integrated flush syringe assembly with two disinfection units containing absorbent materials, disinfectants, and peelable seals, using threaded luer lock connections and snap-fit interlocks. The patent contains 19 claims covering dual-cup assemblies with antimicrobial agents for disinfecting medical connector access ports. Medical device manufacturers and competitors should review the granted claims to assess IP scope and freedom-to-operate implications for similar fluid delivery and disinfection products.

Fisher & Paykel Healthcare, US Patent B2, 7th Apr

Fisher & Paykel Healthcare, US Patent B2, 7th Apr

Movable Tip Bougie Device

USPTO granted patent US12594392B2 to Imam Abdulrahman Bin Faisal University for a movable bougie tip device. The device features a tip section with holder and recoiled wire, and a bougie section with slide button for adjusting tip angle between 30° and 90°. The device prevents kinking via a recoiled wire mechanism and uses silk thread threading through an opening in the tip. Application 17994768 was filed November 28, 2022 with 17 claims.

Impact of Eating Disorders Study

NIH registered observational clinical trial NCT07534059 titled 'Impact of Eating Disorders Study' on ClinicalTrials.gov. The study examines eating disorders including anorexia nervosa and bulimia nervosa in adolescent populations, with estimated prevalence data for anorexia nervosa at 2-3% among young adults and a 5-10% 10-year mortality rate. This is a registry entry providing study information and does not create compliance obligations.

Animal-Shaped Magic Mirrors Reduce Child Vaccination Pain

NIH registered observational study NCT07535151 on April 16, 2026, examining the effect of animal-shaped magic mirrors on pain in children aged 1-4 years during vaccination and maternal anxiety. The single-center study aims to evaluate non-pharmacological interventions for reducing procedural pain in pediatric populations. Results may inform clinical practices for managing vaccination-related distress in young children.

Observational Study Comparing Leadless Pacemakers and Left Bundle Branch Area Pacing

NIH registered clinical trial NCT07534917, an observational acute study comparing leadless right ventricular pacemakers and temporary left bundle branch area pacing on cardiac function and tricuspid valve. Both procedures conducted in one sitting under general anesthesia. Participants referred for routine pacemaker implantation may enroll. The study aims to guide pacemaker type selection for patients at risk of valve or heart dysfunction.

PancreasPlus App Monitors Pancreatic Cancer Patients

NIH ClinicalTrials.gov registered study NCT07532590 evaluating the PancreasPlus mobile app for pancreatic cancer patients. The single-arm feasibility study will assess patient engagement, questionnaire completion rates, perceived service quality, and anxiety reduction through use of the app for remote symptom monitoring and caregiver support. The study anticipates enrolling patients over an undefined period with a primary completion date of April 16, 2026.

Rescue Treatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing

NIH's ClinicalTrials.gov has registered a new Phase 4 clinical trial (NCT07533422) evaluating fecal-based antimicrobial resistance gene testing to guide personalized Helicobacter pylori rescue therapy. The study will enroll patients who have failed initial treatment and compare personalized treatment based on fecal resistance profiles against conventional quadruple therapy, measuring eradication rates and safety outcomes.

OMT vs Exercise in TMD Clinical Trial

NIH ClinicalTrials.gov registered a randomized clinical trial (NCT07534540) comparing osteopathic manipulative treatment (OMT) versus a structured home-based exercise program in adults diagnosed with myogenic temporomandibular disorders (TMD). The trial will assess pain intensity, functional outcomes, postural stability, and quality of life across intervention groups. Enrollment status and specific trial sites are not detailed in the registry record.

Characterization of Pulp Inflammation: Observational Study Using Biological Samples

NIH registered ClinicalTrials.gov study NCT07533396, an observational investigation of pulpal inflammation using biological samples collected during routine dental care. The study aims to validate a new diagnostic classification (Endolight) for guiding vital pulp therapy indications and to identify molecular and protein biomarkers associated with inflammatory severity. The trial enrolls patients undergoing routine dental procedures and requires collection of biological samples for analysis.

Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study

NIH registered a clinical trial (NCT07533526) on ClinicalTrials.gov comparing instrument-assisted constant-speed injection versus manual injection for subcutaneous administration of pertuzumab and trastuzumab in breast cancer patients. The randomized, self-controlled study plans to enroll 40 female patients, with each receiving both injection methods across two treatment cycles. Pain intensity will be measured using the Numerical Rating Scale immediately after injection.

Post-Debonding Finishing in Orthodontics - Observational Study NCT07534423

NIH registered observational study NCT07534423 investigating clinical approaches to orthodontic debonding and post-debonding finishing, focusing on enamel preservation. The study conducted an observational epidemiological survey among dental professionals to assess techniques, instruments, and complications. Results highlight variability in clinical protocols, with mechanical methods being most widely adopted, and emphasize minimally invasive strategies to reduce enamel damage and improve patient outcomes.

GT307 TIL Injection Clinical Trial for Metastatic Solid Tumors

NIH ClinicalTrials.gov registered a new single-center, single-arm, open-label clinical study (NCT07534813) evaluating GT307, an autologous tumor-infiltrating lymphocyte (TIL) injection, in patients with advanced solid tumors. The Phase I/II trial will assess safety, tolerability, pharmacokinetics, efficacy, and optimal dosing. The study is registered with an anticipated start date of April 16, 2026.

Philips Ingenia and Achieva MRI Systems - MRE Liver Stiffness Measurement Recall

Health Canada has issued a Type I recall for Philips Ingenia and Achieva MRI Systems following identification of two software issues affecting diagnostic accuracy. The primary issue involves MRE (Magnetic Resonance Elastography) stiffness measurements where default scan protocol voxel size settings are too small, potentially producing inaccurate (lower) liver stiffness values. A secondary issue affects Philips Vue Motion v12.2.0-v12.2.8.500 where mis-ordered image frames during dynamic cine runs may display out of sequence. Affected products include multiple Ingenia and Achieva 3.0T models with specific lot numbers.

Dose-Response Effect of Phosphatidylserine on eSport Performance

NIH registered a new randomized, double-blind, placebo-controlled clinical trial (NCT07533032) evaluating daily phosphatidylserine supplementation at 100 mg or 200 mg doses in healthy adult gamers over 6 weeks. The study will measure electronic gaming performance, cognitive function, sleep quality, stress outcomes, and heart rate variability at baseline, Week 3, and Week 6. Enrollment includes approximately 75 participants assigned to three parallel groups.

Brepocitinib Phase 2/3 Trial for Lichen Planopilaris in Adults

NIH ClinicalTrials.gov registered a Phase 2/3 study (NCT07532603) evaluating oral brepocitinib versus placebo in adults with lichen planopilaris. The trial will assess clinical safety and efficacy of the investigational drug. Registration posted April 16.

JSKN016 Phase III Trial for Triple-Negative Breast Cancer

NIH registered a Phase III clinical trial (NCT07533123) evaluating JSKN016 versus Treatment of Physician's Choice in patients with unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer (TNBC) who have failed standard of care. The randomized trial will assess progression-free survival and overall survival as primary endpoints. Investigational interventions include JSKN016 Injection and multiple comparator chemotherapies including eribulin, vinorelbine, capecitabine, gemcitabine, and sacituzumab govitecan.

PGT-A Upgrade International Multicenter Observational Clinical Trial

The NIH ClinicalTrials.gov registry has recorded a new international multicenter observational clinical trial (NCT07533630) evaluating PGT-A upgrade testing for preimplantation genetic testing in assisted reproductive technology. The study will enroll patients from seven domestic and international centers to assess embryo utilization rates and clinical outcomes including birth defects following PGT-A upgrade testing. Patient enrollment is expected to be completed within one year.

Shouhui Tongbian Capsule Phase 3 OIC Trial in Cancer Patients

NIH ClinicalTrials.gov registered Phase 3 trial NCT07534995 for Shouhui Tongbian Capsule in treating opioid-induced constipation (OIC) in cancer patients. The prospective, multicenter, randomized, parallel-controlled superiority trial will evaluate symptom-relieving effects including defecation frequency, stool consistency, symptom scores, and quality of life. Primary efficacy endpoint is proportion of responders at week 2, defined as increase of at least 1 in average weekly spontaneous bowel movements. Safety endpoints include adverse event incidence and vital sign changes.

Novel Infant Formula Randomized Trial, Ages 12-18 Months

NIH has registered a new randomized controlled clinical trial on ClinicalTrials.gov (NCT07534735) to evaluate the effects of investigational infant formulas on growth, gut health, immune function, and sleep in healthy infants aged 12-18 months. The three-arm study will compare two investigational formulas against a control.

Phase 4 Elagolix vs OCPs Endometriosis Pain Clinical Trial NCT07532876

NIH's ClinicalTrials.gov has registered a Phase 4 clinical trial (NCT07532876) comparing Elagolix to oral contraceptive pills (OCPs) for reducing endometriosis-associated pelvic pain. The randomized, open-label study aims to provide direct evidence on relative effectiveness and safety to help physicians make more tailored treatment decisions for patients with diagnosed endometriosis. Elagolix is an oral GnRH antagonist intervention.

Placebo-Induced Hypoalgesia During TENS Application in Low Back Pain

NIH's ClinicalTrials.gov registered a randomized controlled trial (NCT07535047) evaluating transcutaneous electrical nerve stimulation (TENS) combined with video-based education for acute low back pain. The study will enroll participants divided into control group (standard physical therapy with TENS and exercises) and experimental group (standard therapy plus video-based TENS educational explanation). The primary outcome measures are feasibility of conducting the full RCT, including recruitment, compliance, and adverse events. Secondary outcomes include pressure pain threshold, pain intensity, functional mobility, patient satisfaction, and quality of life.

Blood Flow Restriction Parameters and Lower Limb Function in Older Adults With Dynapenia

NIH registered clinical trial NCT07534150, a two-phase study examining limb occlusion pressure (LOP) measurements and muscle electrophysiology in older adults with dynapenia. Year one collects baseline LOP data and influencing factors; year two uses high-density surface electromyography to analyze motor unit recruitment under varying BFR pressures. No regulatory obligations imposed.

Effect of Different Volumes of Erector Spinae Plane Block on Postoperative Opioid Consumption After Total Abdominal Hysterectomy

NIH's ClinicalTrials.gov has registered a new observational study (NCT07533760) investigating the effects of different volumes of ultrasound-guided erector spinae plane block on postoperative pain and opioid consumption in patients undergoing total abdominal hysterectomy. The study will evaluate whether varying local anesthetic volume reduces morphine requirements and improves pain scores during the first 24 hours after surgery. No compliance obligations or regulatory actions are associated with this trial registration.

Texas Medical Board Suspends Physician Giraldi Over Public Threat

The Texas Medical Board temporarily suspended Dr. Rodolfo Garma Giraldi's medical license effective April 13, 2026, after finding his continuation in practice poses a continuing threat to public welfare. The suspension stems from his arrest and indictment for aiding or abetting the unlicensed practice of medicine, deviations from standard of care affecting 10 patients, and medical recordkeeping violations. The temporary suspension remains in place until the Board takes further action.